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ABSTRACT 
AN INVESTIGATION INTO THE DETERMINATION OF RELATIVE 
CHROMOSOME DOSAGE BY DIGITAL PCR 
Submitted by CHAN Ka Ying for the degree of Master of Philosophy in Chemical 
Pathology at The Chinese University of Hong Kong in August 2009 
Testing for fetal chromosomal aneuploidy is a common indication for prenatal 
diagnosis. For example, fetal trisomy 21 occurs with an incidence rate of one in 800 
live births. Current methods of prenatal diagnosis of fetal chromosomal aneuploidy 
include amniocentesis and chorionic villus sampling. However, due to their invasive 
nature, both methods have a finite risk of procedure-related fetal loss. Therefore, 
non-invasive prenatal diagnosis such as by the detection of fetal DNA in maternal 
plasma is much desired. 
Recently, our group developed a digital PCR based method for the detection of fetal 
trisomy 21. The method was named digital relative chromosome dosage (RCD) and 
was based on the detection of an additional dose of chromosome 21 sequences as 
expected for a trisomy 21 fetus relative to a reference non-trisomic chromosome. In 
this thesis, I explored if the digital RCD approach could be used as a non-invasive 
alternative to existing analytical strategies for fetal chromosomal aneuploidy 
detection. Since fetal DNA contributes only a minor fraction of the total DNA in 
maternal plasma, the amount of chromosome 21 DNA sequences released into 
maternal plasma from a trisomy 21 fetus would only be slightly higher than that from 
a euploid fetus. 
When applying the digital RCD approach for non-invasive fetal trisomy 21 detection, 
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a major difficulty lies in the low fractional fetal DNA concentration which requires a 
great number of template molecules to be analysed to achieve high diagnostic 
accuracy, as shown in our previous study. Therefore, in this thesis, I developed a 
multiplex digital RCD assay that amplified four sets of paralogous sequences 
between chromosome 21 and other reference chromosomes. I applied the multiplex 
assay on euploid or trisomy 21 placental genomic DNA and artificial mixtures of 
euploid or trisomy 21 placental genomic DNA and maternal buffy coat DNA. All 
cases analysed were correctly diagnosed. This proof-of-principle project 
demonstrates that multiplexing is an approach that allows an increased number of 
template molecules to be analysed per unit volume of plasma. This strategy would 
therefore bring us closer to the realisation of non-invasive prenatal diagnosis of fetal 
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SECTION I: BACKGROUND 
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Prenatal diagnosis of fetal trisomy 21 
CHAPTER 1: PRENATAL DIAGNOSIS OF FETAL TRISOMY 21 
1.1 Down syndrome 
Down syndrome, or trisomy 21 (T21), is a chromosomal abnormality caused by the 
presence of an extra copy of chromosome 21 (chr21), either in whole or in part. It 
occurs with an incidence rate of one in 800 live births (Mutton et al. 1991; Yang et al. 
2002), and is a common indication for prenatal diagnosis. Trisomy 21 is typically 
caused by meiotic nondisjunction, in which a gamete with an extra copy of chr21 is 
produced. When combined with a normal gamete, the embryo would have 47 
chromosomes, with 3 copies of chr21. Meiotic nondisjunction accounts for 95% of 
all Down syndrome cases. Occasionally, part of chr21 breaks off and attaches to 
another chromosome. This would lead to translocation Down syndrome in the 
resulting embryo, with two normal copies of chr21 and extra chr21 genetic material 
attached to another chromosome. This accounts for the other 3-4% of the Down 
syndrome cases. 
Down syndrome is characterised by impairment in cognitive ability, characteristic 
facial features and other health problems. The life expectancy of people affected is 
about 55 years, and they are more likely to die from congenital heart defects and 
leukaemia (Robison 1992; Yang et al 2002). They may suffer from health and 
cognitive problems such as heart defects, intestinal malformations, hearing loss 
(Mazzoni et al. 1994)，infections, vision problems including near-sightedness, 
far-sightedness and cataracts, and memory loss. The severity of these symptoms 
varies among individuals. Facial characteristics include round faces, eyes that slant 
upwards, small ears, small noses, flattened nasal bridges, short necks, and small 
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hands with short fingers. Children or adults with Down syndrome generally look 
short, with unusual looseness of the joints. 
The risk of fetal Down syndrome increases with the maternal age, from 5 per 1,000 
at age 35，to 15 per 1,000 at age 40，and 50 per 1,000 at age 45 (Hook et al 1983). 
Screening tests, for example, maternal serum biochemical tests and ultrasonography, 
are used to risk-stratify pregnant women. However, for definitive diagnostic testing, 
amniocentesis or chorionic villus sampling (CVS) is required. 
Down syndrome can neither be cured nor prevented. Some women with confirmed 
Down syndrome babies may terminate their pregnancies, while others prepare 
medically, emotionally and financially for the birth of their children with special 
needs. 
1.2 Current methods of prenatal diagnosis of fetal trisomy 21 
1.2.1 Non-invasive procedures 
Ultrasonography and maternal serum biochemistry (Malone et al. 2005) are two 
non-invasive methods commonly used for screening. Ultrasound screening for the 
assessment of nuchal translucency has been commonly used since its introduction in 
early 1990s (Malone and D'Alton 2003; Nicolaides et al. 1992; Snijders et al 1998; 
Wald and Hackshaw 1997). An ultrasound nuchal translucency scan measures the 
amount of subcutaneous fluid at the back of the neck of the fetus. This is performed 
between 11 and 13 weeks of gestation. Fetuses affected by chromosomal 
aneuploidies tend to have a larger amount of fluid, causing this clear space to be 
larger than average. Measurement of nuchal translucency, together with the maternal 
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age, gestational age and the presence or absence of the fetus's nasal bone are then 
used to calculate the risk of the fetus having chromosomal aneuploidies. Nuchal 
translucency alone has approximately a 60% detection rate，with a 5% false-positive 
rate (Canick et al 2003). However, ultrasound scanning needs to be performed by 
specially trained doctors or technicians, and no definitive answers can be given. It 
only gives a risk evaluation. 
Pregnant women may also take a blood test for risk assessment by maternal serum 
biochemistry. The second trimester quadruple screening test, which is done at about 
16 weeks of gestation, measures the levels of alpha-fetoprotein (AFP), unconjugated 
estriol (uE3), inhibin A and human chorionic gonadotrophin (hCG). In a Down 
syndrome affected pregnancy, there will be lower levels of maternal serum AFP and 
uE3 but elevated levels of hCG (either intact or free p subunit) and inhibin A (Aitken 
et al 1996; Canick et al 2003). The first trimester combined screening, which 
measures the nuchal translucency, pregnancy-associated plasma protein A (PAPP-A), 
and the free (3 subunit of hCG at about 10-14 weeks of gestation, can also be 
performed (Malone et al 2005). The risk of having a Down syndrome fetus is then 
calculated, taking into account the maternal age and weight. Again, no definitive 
diagnosis is provided. If the probability is greater than 1 in 250，invasive diagnostic 
procedures would be suggested. The detection is about 80% with a false-positive rate 
of 5% for the second-trimester quadruple screening test (Canick et al 2003) and 85% 
with a false-positive rate of 5% for the first-trimester combined screening test (Wald 
et al 1997). The fully integrated screening, which measures nuchal translucency and 
PAPP-A in the first trimester, and also the quadruple markers in the second trimester, 
has a higher detection rate of 94% at a 5% false positive rate (Wald et al 2003). 
However, the main disadvantage is that it cannot provide early results to women as 
4 
Prenatal diagnosis of fetal trisomy 21 
the risk is calculated in the second trimester with inclusion of the marker levels 
measured in the first trimester (Malone et al 2005). 
Both ultrasonography and biochemical screening have their limitations. Since both 
methods target epiphenomena associated with the fetal chromosomal aneuploidies, 
instead of the core molecular abnormalities, they have limited sensitivities and 
specificities. Also, specific tests have strictly defined gestational age windows within 
which they can be used (Lo and Chiu 2008). 
1.2.2 Invasive procedures 
For definitive diagnosis, invasive procedures such as amniocentesis and chronic 
villus sampling are required. Amniocentesis is typically performed between 16 to 18 
weeks of gestation. A hollow needle, guided by ultrasound imaging, is inserted 
through the abdominal wall into the uterus and a small amount of amniotic fluid is 
withdrawn. Amniocentesis leads to increased risks of amniotic fluid leakage and 
other complications (Nikkila et al 2002). The post-procedural rate of fetal loss is 
between 0.5% and 1% (Wilson 2000). 
Chorionic villus sampling involves the removal of a small piece of placental tissue, 
or chorionic villi, during early pregnancy. This can be done through the cervix or the 
abdomen. The sampling is done by an experienced healthcare provider, again guided 
by ultrasound. The transcervical procedure is performed by inserting a thin plastic 
tube through the vagina and cervix to the placenta from where a small sample of 
chorionic villus tissue is removed. The transabdominal procedure, which has been 
shown to have a lower risk of fetal loss (Brambati et al. 1998; Smidt-Jensen et al 
1992)，is performed by inserting a needle through the abdomen and the uterus to the 
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placenta for sample taking. CVS can be performed earlier than amniocentesis, at 
about 10 to 12 weeks after the last menstruation. The risk of CVS is about the same 
as that for amniocentesis, with possible complications including bleeding and 
infection. It is also associated with limb reduction defects of the fetuses (Firth et al. 
1994). False diagnosis may result from confined placental mosaicism (Wapner 2005). 
From either amniocentesis or CVS, fetal cells are obtained. After cell culturing, fetal 
chromosomes are extracted and karyotyping is performed for chromosome analysis. 
Giemsa banding techniques are commonly used for karyotyping. The chromosomes 
are paired, stained and seen under the microscope. The size, shape and number of 
chromosomes in the sample are examined to check for any chromosomal 
abnormalities. 
Although definitive diagnosis can be achieved by conventional cytogenetic study, it 
takes about two weeks to perform chromosome analysis due to the cell culturing 
procedures. This time-consuming process creates great anxiety for parents waiting 
for the results. Therefore, quantitative fluorescent polymerase chain reaction 
(QF-PCR), a more rapid approach giving results in 24 hours may be useful (Leung et 
al 2002; Leung et al 2008). QF-PCR is the amplification and quantification of 
specific genomic DNA regions from uncultured amniocytes with PGR (Levett et al 
2001). DNA is first extracted from uncultured amniocytes. Small tandem repeat 
markers are then amplified with multiplex PGR. A number of DNA markers are 
amplified for each type of chromosomal aneuploidy tested. The resulting PGR 
products are then separated by electrophoresis on a DNA sequencer, and the DNA 
representing each allele for each specific marker is quantified by the peak area. The 
peak area ratios are then calculated for aneuploidy detection. To draw a conclusion, 
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at least 2 informative markers have to give consistent results (Levett et al. 2001). 
Several groups demonstrated the effectiveness and reliability of QF-PCR for 
aneuploidy detection (El Mouatassim et al. 2004; Toth et al 1998; Verma et al 1998). 
QF-PCR is diagnostic for autosomal aneuploidies, with a detection rate of 100% in a 
study (Levett et al 2001). Only a small amount of amniotic fluid is needed, with no 
cell culturing required. However, QF-PCR relies on the specific markers being 
heterozygous, and is therefore polymorphism-dependent. Also, mosaics and 
translocations are unlikely to be detected. 
Amniocentesis and CVS provide definitive diagnostic results. However, they are 
invasive and have a finite risk of post-procedural fetal loss (Tabor et al 1986). They 
are therefore recommended for high-risk pregnancies only. It would be ideal if 
non-invasive diagnostic methods could be developed for aneuploidy detection. 
1.3 Alternative methods for the prenatal diagnosis of fetal trisomy 21 
Apart from the aforementioned methods, other methods were developed by different 
groups for the same purpose. Zimmermann et al performed multiplex real-time PCR 
assay in which the amyloid gene in the Down syndrome critical region of chr21 and 
the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) locus on chrl2 were 
co-amplified (Zimmermann et al 2002). DNA extracted from amniocyte cultures 
from T21 fetuses and healthy controls was analysed. The ratio of the 2 loci was then 
determined by the difference in threshold cycle value (ACT). In their study, the 
euploid and T21 samples could be clearly separated, allowing rapid and automated 
determination of trisomy 21. However, both loci must be amplified with equal 
efficiency over the exponential phase of the real-time PCR. Moreover, since a 2-fold 
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difference in DNA template concentration constitutes only a difference of one 
threshold cycle, the discrimination of the 1.5-fold difference in T21 samples has been 
the limit of conventional real-time PCR (Lo et al 2007a). 
The other method used for the prenatal diagnosis of fetal trisomy 21 is the 
quantitative fluorescence in situ hybridisation (FISH) approach on interphase nuclei 
(Truong et al. 2003). In this approach, the relative numbers of chr21 and chr22 in 
interphase nuclei were measured. Chr22 was chosen as the reference chromosome 
due to its similar size to chr21, and that trisomy 22 would lead to early abortion. 
Cells from amniotic fluid samples from euploid and T21 fetuses were analysed. 
Chromosomes 21 and 22 were labelled by different fluorescent probes. Hybridisation 
signals from both chromosomes were separately quantified by an automated image 
analyser and the chr21/chr22 ratio was calculated for each nucleus. The fluorescence 
ratios for all nuclei were plotted on a histogram and the mean value was taken as the 
chr21/chr22 ratio for each sample. The number of chr21 was calculated by dividing 
the chr21/chr22 ratio of the sample by that from the reference control sample. 
Euploid samples should give a ratio of 1 while T21 samples should give a ratio of 1.5. 
In the study (Truong et al. 2003)，all analysed cases showed 100% concordance with 
conventional cytogenetics. Several groups also reported the use of this approach as a 
sensitive and reliable technique for the prenatal diagnosis of chromosomal 
aneuploidy (Pierluigi et al. 1996; Thilaganathan et al 2000; Witters et al. 2002). 
However, this approach is influenced by the hybridisation efficiency and the variable 
signal intensity within the nuclei (Truong et al. 2003). Also, it is relatively labour 
intensive. 
Analysis of chromosome copy number by visual scoring leads to technical bias due 
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to spot heterogeneity and out-of-focus spots (Tmong et al 1997). With standard 
microscopy, FISH analysis is expensive and requires a high level of skill and 
subjective signal interpretation. The detection may be improved by automated 
recording and analysis. The recent development of automated microscopy (Wauters 
et al. 2007) allows more rapid screening for common chromosome abnormalities. 
Automated microscopy allows automated evaluation and analysis of FISH signals, 
and reports their enumeration for each channel. Optimal images can be acquired by 
automated exposure setting and focusing. Using a fully automated system for FISH 
analysis could lead to improvement in laboratory efficiency and reduction in errors 
and costs. Automation may also increase the number of cells analysed, leading to 
higher detection sensitivities. In a study by Wauters et al., they compared the 
efficiency of an automated system with a standard manual analysis (Wauters et al. 
2007). Amniocytes were analysed with manual and automated microscopy for the 
detection of fetal chromosomal aneuploidies. The results indicated that automated 
microscopy allows accurate and rapid enumeration of FISH signals in amniocytes. 
The diagnostic outcomes provided by manual and automated microscopy were 100% 
concordant (Wauters et al. 2007). Automated microscopy also provided another 
advantage that a sample can be re-evaluated to confirm the diagnosis by reviewing 
the images. Given all these advantages, automated microscopy should be highly 
desirable. 
Another approach for the prenatal diagnosis of fetal trisomy 21 is the multiplex 
ligation-dependent probe amplification (MLPA) technique. MLPA is a technique that 
can detect trisomies, exon deletions and duplications, and allows the characterisation 
of chromosomal aberrations (Schouten et al. 2002). In MLPA, the probes added to 
the samples, instead of the sample DNA itself, are amplified and quantified. Each 
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probe consists of 2 oligonucleotides that hybridise to adjacent sites of the target 
sequence. Both oligonucleotides consist of a short target-specific sequence and a 
universal primer-binding site. One of the oligonucleotides also contains a stuffer 
sequence with specific length and sequence for each probe. The hybridised probes 
are ligated by ligase enzyme, after which PGR amplification is performed. All the 
probes are simultaneously amplified by one fluorescently labelled primer pair. 
Amplification products of a unique size would be produced from each probe. The 
amplification products are then analysed by capillary electrophoresis, by which they 
are detected and quantified. For the detection of fetal trisomy 21，CVS or amniotic 
fluid samples can be analysed by MLPA. Probes are designed for chr21 sequences, 
and the ratio of each individual probe relative area is then normalised to that of a 
control sample. The relative probe signals obtained would then reflect the relative 
amounts of the probe target sequences in the samples. The presence of an extra copy 
of chr21 target sequences in T21 fetuses can then be detected (Schouten et al 2002). 
An outline of MLPA reaction is shown in Figure 1.1. Studies showed that MLPA is a 
rapid, reliable and simple method for the detection of chr21 aneuploidy (Gerdes et al 
2008; Kooper et al 2008). The equipment required for MLPA analysis is present in 
many molecular biology laboratories. However, MPLA may not be able to detect 
cases of mosaicism and chromosomal rearrangement (Kooper et al. 2009). 
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MLPA, Multiplex Ligation-dependent Probe Amplification 
• Denatured genomic DNA is hybridized with a mixture of 40 probes. 
• Each MLPA probe consists of two oligonucleotides, one synthetic and 
one M13-derived. 
PCR primer sequen^Y / pcR primer sequence X 
/ Stuffer 
Hybridisation § sequence Each M13 derived probe 
sequence Hybridisation oligonucleotide has a 
sequence different stufFer sequence. 
J > 
/ / The two parts of each 
� f . . y / probe hybridise to 
3' Target A 5’ / adjacent target 
3’ Target B 5， 卿ences 
� ’ 7 
7 / The two parts of 
Y / hybridised probes are 
^ ^ ^ / iigated by a thermostable 
3’ 丁argetA 5, Ta rge ts 5' 
Ail probe ligation products are amplified by PCR using only one primer pair. 
Y X Y X The amplification product of 
" " " " " " " " " " " c. each probe has a unique 
5' 3， 5 3 length <130-480 bp). 
Amplification products are separated by electrophoresis. Relative amounts of 
probe amplification products reflect the relative copy number of target sequences. 
Figure 1.1 An example of MLPA reaction. 
(Adapted from Figure 2，Schouten et al. 2002) 
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Concluding remark 
This chapter describes non-invasive, invasive and alternative methods for the 
prenatal diagnosis of fetal trisomy 21. These methods allow the detection of fetal 
trisomy 21 with different sensitivities and specificities, and have different strengths 


























































































































































































































































































































































































































































































































































































































































































































































Cell-free fetal nucleic acids in maternal plasma 
CHAPTER 2: CELL-FREE FETAL NUCLEIC ACIDS IN 
MATERNAL PLASMA 
2.1 Circulating fetal cells 
In 1893，a German pathologist, Georg Schmorl, first discovered the presence of fetal 
cells in the maternal body. He performed complete autopsies on 17 women who died 
of eclampsia and identified the presence of multinucleated syncytial giant cells in 
their lungs (Georg 1893; Lapaire et al 2007). He speculated that these cells 
originated from the placenta, and his discoveries were confirmed by other groups 
(Bianchi et al 1990; Chua et al 1991; Douglas et al. 1959). Later, the frequency of 
fetal nucleated cells in maternal peripheral blood was also determined by FISH and 
PGR on Y-specific sequences during different stages of pregnancy. Fetal nucleated 
cells can be detected by fluorescence in situ hybridisation (FISH) at and after 15 
weeks of pregnancy and increase in maternal peripheral blood as gestation progresses 
(Hamada et al 1993). After delivery, such fetal nucleated cells decrease in frequency 
with time, and disappear from the maternal circulation 3 months post-partum in most 
mothers (Hamada et al 1994). However, Bianchi et al demonstrated the prolonged 
persistence of fetal progenitor cells in the maternal circulation for as long as 27 years 
post-partum, establishing a long-term, low-grade chimeric state in the mother 
(Bianchi et al 1996). The number of fetal cells in maternal circulation was shown to 
be low, that only one fetal cell is present per mL of maternal blood (Bianchi et al 
1997). 
2.2 Circulating cell-free fetal nucleic acids 
15 
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Extracellular nucleic acids have been reported to be present in human plasma since 
1948 (Mandel and Metais 1948). Some 30 years later, Leon et al, discovered that 
cancer patients had elevated level of circulating cell-free nucleic acids compared to 
normal controls, and those with higher level of circulating nucleic acids after therapy 
generally had poorer prognosis (Leon et al 1977). In 1989，Stroun et al. suggested 
the presence of tumour-derived DNA in plasma (Stroun et al. 1989)，however, this 
was only confirmed when Sorenson et al. and Vasioukhin et al. detected oncogene 
mutations derived from the tumour in the circulation (Sorenson et al. 1994; 
Vasioukhin et al. 1994). In 1997, Lo et al., realising the pseudo-malignant nature of 
the placenta (Strickland and Richards 1992)，first discovered the presence of cell-free 
fetal nucleic acids in maternal plasma, and demonstrated the presence of 
Y-chromosome specific DNA sequences in the plasma of women with male fetuses 
(Loet al 1997). 
It is a common belief that circulating cell-free fetal DNA arises from placental 
trophoblast cells (Alberry et al 2007; Flori et al 2004). Apoptosis of fetal 
erythroblasts through fetomatemal cellular trafficking is also a possible mechanism 
of fetal DNA release (Sekizawa et al 2000; Zhong et al. 2002). However, the most 
accepted hypothesis is the direct release from the placenta due to cellular apoptosis 
(Tjoa et al 2006). Most circulating fetal DNA molecules are short in length, with 
80% of them being less than 200 bp (Chan et al 2004). They represent only a small 
fraction of cell-free DNA in maternal plasma, contributing some 10% (Lo et al 
1998b; Lun et al 2008a) of the total DNA. Circulating fetal DNA started to be 
detectable in maternal plasma as early as on day 18 after embryo transfer by assisted 
reproduction (Guibert et al 2003). Concentration of fetal DNA in maternal plasma 
increases as gestation progresses (Lo et al. 1998b), amounting to a mean of 25 
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genome-equivalents (GE) per rtiL in early pregnancy and 292 GE per mL in late 
pregnancy (Bianchi 1998; Lo et al. 1998b). Post-delivery clearance of fetal DNA 
from maternal plasma is extremely rapid, with a mean half-life of about 16 minutes 
{hoet al 1999). 
Circulating cell-free fetal DNA offers advantages over circulating fetal cells. The 
first advantage is that in the second trimester of pregnancy, the concentration 
cell-free fetal DNA is about 970-fold higher than the cellular fraction, providing an 
abundant source of fetal nucleic acids for analysis (Lo et al 1998b; Tsang and Lo 
2007). The second advantage is that post-delivery clearance of fetal DNA in maternal 
plasma is extremely rapid. This rapid kinetics allows monitoring of pregnancy in an 
almost real-time fashion (Lo et al 1999). Therefore, many diagnostic applications 
have been developed using cell-free fetal DNA. 
2.3 Diagnostic applications of cell-free fetal nucleic acids in maternal plasma 
The discovery of this new, non-invasive source of fetal DNA in maternal plasma 
opened up new possibilities for non-invasive prenatal diagnosis. It has been used for 
the prenatal determination of fetal RhD status in RhD-negative pregnant women 
(Finning et al 2008; Lo et al 1998a), the prenatal diagnosis of neurological 
disorders (Amicucci et al 2000), the determination of fetal gender in diseases such 
as haemophilia (Costa et al. 2002; Santacroce et al 2006) and congenital adrenal 
hyperplasia (Rijnders et al. 2001)，and the prenatal detection of paternally inherited 
mutations in single gene disorders such as beta-thalassaemia when the paternal and 
maternal mutations are different (Chiu et al 2002; Ding et al 2004). Among the 
various applications, the RhD blood group genotyping technology has been 
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translated to clinical service in some European countries and the U.S.A. (Finning et 
al. 2004; Gautier et al, 2005; Hillyer et al 2008; Roque 2006). 
However, the use of cell-free fetal DNA in maternal plasma for the determination of 
fetal chromosomal aneuploidies has been technically challenging. The first obstacle 
is that fetal DNA coexists in a high background of maternal DNA which causes 
interference to the analysis (Lo et al 1998b). The second obstacle is that the fetal 
DNA exists in the maternal circulation in cell-free form, so chromosome dosage 
information is difficult to obtain. Although fetal DNA quantification in maternal 
plasma by the microfluidics digital PCR platform recently revealed a higher fraction 
of fetal DNA than previously reported, with fetal DNA contributing 9.7%, 9.0%, and 
20.4% of total DNA in the first, second, and third trimesters, respectively, fetal DNA 
is still the minor population. 
To detect fetal chromosomal aneuploidies, different approaches have been developed. 
One approach is the placental RNA-single nucleotide polymorphism (SNP) allelic 
ratio approach. The presence of fetal derived mRNA in maternal plasma was first 
demonstrated by Poon et al. (2000)，and has opened up new possibility for prenatal 
diagnosis, particularly in monitoring the gene expression pattern of the fetus in 
physiological and pathological complications. In the RNA-SNP approach, the 
chromosome dosage is derived by analyzing placental expressed mRNA in maternal 
plasma. The ratio between alleles of a SNP in placenta-specific 4 (PLAC4) mRNA, a 
fetal-specific marker which is transcribed from chr21 and expressed by the placenta 
in maternal plasma, is determined (Lo et al. 2007b). If the fetus heterozygous for this 
SNP is euploid, it would have two copies of the PL AC4 gene, thus the ratio of the 
two SNP alleles would be 1:1. The ratio of placental mRNA released in maternal 
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plasma from the two alleles would also be 1:1. On the other hand, if the heterozygous 
fetus is affected by T21, the RNA-SNP allelic ratio would be 1:2 or 2:1. The 
RNA-SNP allelic ratio can be measured by mass spectrometry, and Lo et al. (2007) 
have demonstrated that fetal T21 can be detected non-invasively with 90% sensitivity 
and 96.5% specificity. 
Another approach is the detection of fetal-specific nucleic acids with a 
placenta-specific DNA methylation pattern. This approach, involving the analysis of 
epigenetic allelic ratio of fetal-specific epigenetic markers, has been used for the 
prenatal detection of fetal trisomy 18. The epigenetic marker used was the 
SERPINB5 gene coding for maspin on chrl8, which is hypomethylated in the 
placenta but hypermethylated in maternal blood cells (Chim et al 2005; Tong et al. 
2006). By measuring the SNP allelic ratio in the hypomethylated gene, the trisomy 
18 status of the fetus can be determined. To achieve prenatal diagnosis of fetal T21 
by the epigenetic approach, there is an intense search for fetal-specific epigenetic 
markers on chr21 (Chim et al. 2008; Old et al 2007; Papageorgiou et al. 2009), and 
Chim et al. showed that 22 out of the 114 studied genomic regions had differential 
methylation between the maternal and placental tissues (Chim et al 2008). These 
DNA methylation markers may be used for the non-invasive prenatal detection of 
trisomy 21. 
Comparing the RNA-SNP and the epigenetic allelic ratio approach, one advantage of 
the former over the latter is that gene transcription in the placenta produces multiple 
copies of mRNA (Lo 2008). Circulating RNA is unexpectedly stable, with human 
placental lactogen and phCG mRNA in maternal plasma being stable for up to 24 
hours at room temperature, making it a suitable diagnostic tool (Ng et al 2003; 
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Wong and Lo 2003). Another advantage is that in RNA-SNP one can simply detect 
mRNA by reverse transcriptase PCR, unlike the epigenetic approach which requires 
bisulphite conversion and the use of bisulphite-based reagents (Lo 2008; Lo 2009). 
Since such reagents have been shown to reduce the amount of target DNA available 
for downstream analysis by causing DNA degradation (Grunau et al. 2001), this is 
particularly detrimental for the detection of fetal specific DNA molecules when they 
are of limited presence in maternal plasma (Lo and Chiu 2008). 
Both the RNA-SNP approach and the epigenetic allelic ratio approach target 
fetal-specific molecules in maternal plasma, thus overcoming the problem of 
maternal background interference. However, the main limitation of both approaches 
is that they can only be applied on fetuses heterozygous for the analysed SNP. For 
example, in the RNA-SNP approach, with the use of one SNP in the PLAC4 mRNA, 
approximately only 45% of fetuses would be heterozygous where the test would be 
relevant (Lo 2009). Multiple SNPs could be used to increase the rate of 
heterozygosity to cover a larger population (Go et al. 2007)，but nevertheless, the 
dependence on genetic polymorphisms limits the use of both approaches. 
2.4 Digital relative chromosome dosage approach 
It would ideal if a non-invasive, gender- and polymorphism-independent method 
targeting the core chromosomal abnormality is developed for the prenatal diagnosis 
of fetal T21. In this regard, the digital relative chromosome dosage (RCD) approach 
(Lo et al 2007a) was developed. Although fractional fetal DNA concentration is low 
in maternal plasma (Lo et al 1998b; Lun et al. 2008a), for each genome equivalent 
(GE) of fetal DNA released into maternal plasma, there would be additional dose of 
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chr21 sequences from a T21 fetus. For instance, at 10% fractional fetal DNA 
concentration, for 50 GE of DNA in maternal plasma, 45 GE of DNA would be from 
the mother and 5 GE of DNA would be from the fetus. For a euploid pregnancy, 
there would be 90 copies of chr21 from the mother and 10 copies of chr21 from the 
fetus, adding up to a total of 100 copies. For a T21 pregnancy, similarly there would 
be 90 copies of chr21 from the mother. However, as each fetal cell now has 3 copies 
of chr21, there would be 15 copies of chr21 from the fetus, adding up to a total of 
105 copies. Therefore, dosage of chr21 in a T21 pregnancy would be 1.05 times that 
of a euploid pregnancy at 10% fractional fetal DNA concentration (Lo et al 2007a). 
The greater the fractional fetal DNA concentration in maternal plasma, the greater 
the degree of chr21 overrepresentation in a T21 pregnancy compared to a euploid 
pregnancy. To detect this small degree of quantitative difference for the detection of 
fetal T21, digital PCR (Vogelstein and Kinzler 1999)，with greater discrimination 
power, was used. 
The concept of digital PCR was described in 1992 by Skyes et al who performed 
DNA quantification by using limiting dilution and counting the number of positive 
amplifications (Sykes et al 1992). In 1997，Kalinina et al. described digital PCR in 
nanolitre scale using glass capillaries and fluorescence detection with TaqMan 
probes (Kalinina et al. 1997). In 1999，Vogelstein et al. performed PCR in a 96-well 
plate format and diluted the input DNA to a concentration that only one template 
molecule was present per two wells (Vogelstein and Kinzler 1999). 
In our digital PCR experiments, the DNA sample is diluted to an extremely low 
concentration such that on average there is only one template molecule per reaction 
well on the 384-well plate. A multitude of single-molecule PCRs are set up (Lo et al 
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2007a). Under such condition, most positive amplifications would represent signals 
from single template molecules (Pohl and Shih le 2004; Vogelstein and Kinzler 
1999). Since DNA quantification is done by virtually counting each copy of template 
molecule, digital PCR offers a much greater precision of measurement, making it a 
suitable technique when a finer degree of quantitative discrimination is needed. 
Digital PCR has been used in various areas including the detection of a mutant ras 
oncogene in stool samples of cancer patients (Vogelstein and Kinzler 1999; Zou et al 
2008b), loss of heterozygosity (LOH) studies of tumour samples (Zhou et al 2001)， 
assessment of allelic imbalance in plasma DNA of ovarian cancer patients (Chang et 
al 2002), measurement of copy number in cancer samples and copy number 
variation studies (Dube et al 2008; McCaughan et al 2008; Qin et al 2008). 
In digital RCD, digital PCR is used to determine the chromosome dosage of chr21 
with reference to another non-trisomic chromosome. To detect fetal T21，a change in 
the ratio of chr21 to the reference chromosome from 2:2 in the genome of a euploid 
fetus to 3:2 in a T21 fetus has to be differentiated. Therefore, for a euploid pregnancy, 
the number of wells positive for chr21 and the reference chromosome should be 
approximately the same, while for a T21 pregnancy, there should be 
overrepresentation of wells positive for chr21 (Lo et al 2007a). However, as 
mentioned, since fetal DNA only contributes a minor fraction of total DNA in 
maternal plasma (Lo et al. 1998b; Lun et al. 2008a), the degree of overrepresentation 
would be much smaller. Therefore, the sequential probability ratio test (SPRT), 
which would be explained in more detail in Chapter 3.6.4, is employed as the 
statistical tool for disease classification. 
2.5 Validation of digital RCD approach on artificial DNA mixtures 
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The digital RCD approach was validated with two euploid and two T21 placental 
DNA samples, and mixtures containing 50% and 25% of euploid and T21 placental 
DNA in a background of euploid maternal blood cell DNA to investigate if digital 
RCD can be applied to non-pure fetal DNA samples (Lo et al 2007a). Ten euploid 
and ten T21 DNA mixtures at 50% fetal DNA and five euploid and five T21 DNA 
mixtures at 25% fetal DNA were analysed. The reference chromosome was chrl, and 
the amplicons were a pair of paralogous sequences (Deutsch et al 2004) on 
chromosomes 21 and 1. The pair of paralogous sequences differed at the paralogous 
sequence mismatches (PSMs) which can be discriminated by TaqMan probes with 
the real-time system. With the SPRT analysis, all the placental samples and the 
euploid and T21 DNA mixtures were correctly classified. One to five 384-well plates 
of digital PGR analyses were needed for the 50% DNA mixtures, while one to seven 
384-well plates were needed for the 25% DNA mixtures to reach disease 
classification (Lo et al 2007a). 
The digital RCD approach was developed to overcome the requirement of 
heterozygosity for approaches such as the RNA-SNP approach and the epigenetic 
allelic ratio approach. Paralogous sequences were chosen as the amplification targets 
so that they could be co-amplified by a common pair of primer for easier 
optimisation. 
However, computer simulation showed that even at a fractional fetal DNA 
concentration of 25%, 7,680 reactions would be needed to correctly classify 97% of 
the euploid and T21 samples without incorrect classification (Appendix I) (Lo et al 
2007a). To capture 7,680 DNA molecules, DNA from 8 mL of maternal plasma 
would have to be extracted. This means 15 mL of whole blood has to be taken from 
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the mother, and this is at the limit of routine practice (Lo et al 2007a). 
To address this problem, in my project, I attempt to combine multiple sets of 
paralogous sequence targets on chr21 and the reference chromosomes for analysis, so 
that more DNA molecules could be counted per unit volume of maternal plasma. 
Indeed, fetal DNA concentration is lower than 25% in maternal plasma, so even more 
template molecules would be needed for disease classification. It is hoped that by 
this multiplex analysis and multiple counting of chr21, lower volumes of maternal 
blood would be needed, making non-invasive prenatal diagnosis of fetal trisomy 21 
with maternal plasma more feasible. 
Concludins remark 
The discovery of non-invasive source of fetal DNA in maternal plasma opened up 
new possibilities for non-invasive prenatal diagnosis. Despite the technical 
challenges such as low fractional fetal DNA concentration, approaches such as the 
RNA-SNP allelic ratio approach, epigenetic allelic ratio approach, and the digital 
RCD approach have been developed for the prenatal diagnosis of fetal trisomy 21. 
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CHAPTER 3: QUANTITATIVE ANALYSIS OF NUCLEIC ACIDS 
3.1 Subject recruitment and sample collection 
All the placental tissue and maternal peripheral blood samples were collected from 
the Department of Obstetrics and Gynaecology, Prince of Wales Hospital, Hong 
Kong, with institutional ethical approval. Subjects with singleton pregnancies were 
recruited with informed consent. Euploid placental tissue samples were collected 
after elective caesarean section at term, while T21 placental tissue samples were 
collected after termination of pregnancy in the first or second trimester. Fetal 
karyotypes were confirmed by full karyotyping. The placental samples were rinsed 
with diethyl-pyrocarbonate (DEPC) (Sigma-Aldrich, St. Louis, MO)-treated water 
and stored at -80 before DNA extraction. 
Maternal peripheral blood samples were collected 24 hours after delivery into 
ethylenediaminetetraacetic acid (EDTA)-containing tubes. They were stored at 4 °C 
before blood processing. • 
3.2 Sample processing 
The maternal peripheral blood samples were first centrifuged at 1,600 g for 10 min at 
4 °C (Centrifuge 5810R, Eppendorf, Germany). The middle layer, i.e. buffy coat, 
which consists mostly of white blood cells and platelets, was transferred to plain 
polypropylene tubes and re-centrifuged again at 2,300 g for 5 min at room 
temperature (Microlitre Centrifuge Z233 M-2，Hermle, Germany). The residual 
plasma was removed, and the remaining maternal blood cells were stored at -20 °C 
until DNA extraction. 
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3.3 Nucleic acid extraction 
3.3.1 Extraction of DNA from placental tissues 
DNA from placental tissues was extracted by the QIAamp DNA Mini Kit (Qiagen), 
according to the manufacturer's tissue protocol. For each sample, 25 mg of placental 
tissues were lysed by 20 |iL of Qiagen proteinase K and 180 i^L of buffer ATL at 56 
°C overnight on a rotating platform. Then, 200 |iL of buffer AL was added to the 
lysate and incubated at 70 for 10 min. After the incubation, 200 jiL of cold 
absolute ethanol was added for the precipitation of DNA. The mixture was 
transferred to a QIAamp Mini Spin Column and centrifuged at 6,000 g for 1 min. 
The Mini Spin Column was washed with 500 |iL of each wash buffer, AWl and AW2， 
respectively. DNA was eluted 3 times with 50 [iL of deionised water for each elution 
and stored at -30 
3.3.2 Extraction of DNA from maternal blood cells 
DNA from the maternal blood cells was extracted by the QIAamp DNA Blood Mini 
Kit (Qiagen), using the body fluid protocol. For each sample, 40 |iL of Qiagen 
protease and 400 \iL of buffer AL were added to 400 |xL of maternal blood cells. The 
mixture was incubated at 56 for 10 min. After the incubation, 400 i^ L of cold 
absolute ethanol was added for DNA precipitation. The mixture was transferred to a 
QIAamp Mini Spin Column and centrifuged at 6,000 g for 1 min. The Mini Spin 
Column was washed with 500 |xL of each wash buffer，AWl and AW2, respectively. 
DNA was eluted twice with 50 |iL of deionised water for each elution and stored at 
-30 oc. 
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3.4 Matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry 
(MALDI-TOFMS) 
The MassARRAY® iPLEX Gold system (Sequenom, San Diego, CA) is a technology 
for single nucleotide polymorphism (SNP) genotyping for sub-whole genome studies. 
It is employed in the fine mapping and validation studies of SNPs (Zou et al 2008a). 
The multiplexing level can be up to 40 SNPs, leading to a throughput level of up to 
150,000 genotypes per instrument per day. This high-throughput genotyping 
application was chosen as the platform for the assays in my project. 
Principle 
In my project, instead of doing SNP genotyping, a pair of paralogous sequences on 
chr21 and another reference non-trisomic chromosome are targeted for the 
determination of chr21 dosage. In the MassARRAY® iPLEX Gold system, the first 
step is the conventional PCR using a single pair of forward and reverse primer to 
co-amplify paralogous sequences on the two different chromosomes. Paralogous 
sequences have high degree of sequence similarity and can therefore be co-amplified 
by a common pair of primer. However, at certain loci there are base substitutions 
which are named paralogous sequence mismatches (PSMs), whose sequences are 
chromosome-specific. Paralogous sequences containing different PSMs are targeted 
on purpose, so that they can be differentiated by the PSMs by the extension primer. 
After the PCR, the unincorporated deoxyribonucleotides (dNTPs) are inactivated by 
treatment with shrimp alkaline phosphatase (SAP). The single base primer extension 
is performed, in which the extension primer anneals to the base next to the PSMs and 
extends by the addition of mass-modified nucleotides to form extension products of 
different masses. Table 3.1 shows the mass differences between the iPLEX Gold 
extension products. Two types of extension products with different PSMs will then 
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be produced, their amount proportional to the amount of template DNA in the 
original sample. The extension products are then analysed by MALDI-TOF MS, in 
which they are separated and detected according to their masses. The base and 
frequency of each extension product are reported, from which the paralogous ratio 
can be calculated. Dosage of chr21 can then be determined with reference to another 
non-trisomic chromosome. This is further illustrated in Figure 3.1. 
Table 3.1 Mass differences between the iPLEX Gold products 
Terminator A C G T 
A 0 -24 16 55.9 
C ^ 0 4Q 79.9 
G -16 ^ 0 39.9 
T -55.9 -79.9 -39.9 0 
Adapted from iPLEX® Gold Application Guide 
(http://www.sequenom.coni/Genetic-Analysis/Applications/iPLEX-Genotyping/iPLEX-Literature) 
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Figure 3.1 Principle of iPLEX® Gold reaction for the determination of chr21 
dosage with MALDI-TOF MS technology. Paralogous sequences on chr21 and the 
reference chromosome are co-amplified by a common pair of forward and reverse 
PCR primer. In the iPLEX® Gold reaction, the extension primer anneals next to the 
PSMs and extends by the addition of mass-modified nucleotides complementary to 
corresponding sequences of the PSMs, so extension products of different masses are 
produced. They are then detected and resolved by MALDI-TOF MS, giving two 
peaks in the mass spectrum. In the figure, PSM denotes paralogous sequence 
mismatch. 
Adapted and modified from iPLEX® Gold Application Guide 
(http://www.sequenom.com/Genetic-Analysis/Applications/iPLEX_Genotyping/iPLEX-Literature) 
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3.5 Paralogous sequence assays optimisation workflow 
In total, three versions of paralogous sequence assays were developed. First, the 
monoplex paralogous sequence assays were designed to select assays capable of 
differentiating euploid and T21 samples which would be used for assembly into the 
multiplex paralogous sequence assay. The multiplex paralogous sequence assay was 
designed to increase the number of countable template molecules by targeting 
multiple pairs of paralogous sequences, so that less volume of maternal blood sample 
would be needed for analysis. Finally, the digital multiplex paralogous sequence 
assay, which was the final aim of the optimisation process, was developed, which 
counted every template molecule by digital PCR so that DNA quantification can be 
done with higher precision and higher discrimination power can be attained. Disease 
classification can then be achieved by data integration from the monoplex assays, 
with a lower volume of blood sample. 
3.5.1 Monoplex paralogous sequence assays 
Forward, reverse and extension primers were designed by the MassARRAY Assay 
Design software (Sequenom), and are summarised in Table 3.2. In my studies, each 
paralogous sequence assay was named starting with PV, denoting the paralogous 
variant, followed by the target chromosomes on which the paralogous sequences 
were amplified. The only exception was the Zinc Finger assay, which amplified Zinc 
Finger Protein sequences on chrX {ZFX) and chrY {ZFY) and was named as ZFY/X 
assay. In case more than one pair of paralogous sequences on chr21 and a reference 
chromosome were selected as targets, a lower case letter was added at the end to 
differentiate the assays. Totally four independent monoplex assays were developed in 
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my studies. The amplification targets of each monoplex assay are as follows. Assay 1， 
PV2101, targets paralogous sequences on chr21 and chrl. Assay 2, PV2107a, targets 
paralogous sequences on chr21 and chr7. Assay 3，PV2102b, targets paralogous 
sequences on chr21 and chr2. Assay 4，PV2106_L, targets paralogous sequences on 
chr21 and chr6, where L denotes the longer extension product length after base 
addition in the optimisation process (Chapter 5). For each assay, a 10-mer tag, 
5'-ACGTTGGATG-3was added to the 5，end of the forward and reverse PCR 
primer so that their masses would be out of the mass detection range of the mass 
spectrometer. 
In a total reaction volume of 25 jiL, 20 ng of extracted placental/matemal blood cell 
DNA was added as the template. The preparation of the initial PCR reaction mixture 
is summarised in Table 3.3 A. AmpliTaq Gold® DNA Polymerase (Applied 
Biosystems, Foster City, CA) was used. The reaction was initiated at 95 for 5 min, 
followed by denaturation at 95 °C for 30 s, annealing at 62 °C for 30 s, extension at 
72 °C for 30 s for 45 cycles, and a final incubation at 72 °C for 7 min. The thermal 
profile of the initial PCR reaction is summarised in Table 3.3 B. 
Shrimp alkaline phosphatase (SAP) treatment was set up to deactivate the 
unincorporated dNTPs in the PCR product. Tables 3.4 A and B summarise the 
preparation of the SAP reaction mixture and the thermal profile respectively. The 
reaction was initiated at 37 °C for 40 min for the activation of SAP enzyme activities, 
followed by 85 °C for 5 min for SAP deactivation. 
The iPLEX® Gold reaction was set up for single base primer extension. Tables 3.5 A 
and B summarise the preparation of the iPLEX® Gold reaction mixture and the 
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thermal profile respectively. The reaction was initiated at 94 for 35 sec, followed 
by annealing at 52 for 5 sec and extension at 80 °C for 5 sec. The annealing and 
extension cycle was repeated four more times for a total of five cycles and then 
looped back to a 94 °C denaturing step for 5 sec, after which was the 5-cycle 
annealing and extension loop again. The five annealing and extension cycles with the 
single denaturing step were repeated 39 times for a total of 40. A final extension at 
72® C for 3 min was performed. After that, 40 |iL of water and 12 mg of 
SpectroCLEAN Resin (Sequenom) were added for cleaning up the final extension 
products. They were rotated and mixed on a rotor for 30 min, followed by a 
centrifugation step at 318 g for 3 min. The extension products were dispensed onto a 
SpectroCHIP (Sequenom) by a MassARRAY Nanodispenser S (Sequenom). Mass 
spectra acquisition was done in the MassARRAY Analyzer Compact Mass 
Spectrometer (Sequenom). Data analysis was done by the MassARRAY Typer 
(Sequenom) software. 
Take the PV2101 assay as an example, for chr21 with PSM C, the primer extension 
product would have the sequence 5 '-GTCTCATCTCTACTTCGTACCTCC-3 ‘ with a 
molecular mass of 7123.7 Daltons (Da). For chrl with PSM T, the primer extension 
product would have the sequence 5'- GTCTCATCTCTACTTCGTACCTCT-3‘ with a 
molecular mass of 7203.6 Da. The mass difference between the two extension 
products would be resolved by the mass spectrometer, giving two distinct peaks in 
the mass spectrum. The peak ratio of the two reaction products could then be used to 
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Table 3.3 Monoplex PV2101/PV2107a/PV2102b/PV2106_L assays. 
(A) Composition of initial PCR mixture (AmpliTaq Gold® DNA polymerase, Applied 
Biosystems) 
^ ^ Volume for one , • Component . Final concentration reaction (|LIL) 
Deionised water 9.775 -
lOx PCR buffer II 3.125 1.25X 
MgCl2 (25 mM) 2.8 2.8 mM 
dATP(lOmM) 1.25 0.5 mM 
dTTP( lOmM) 1.25 0.5 mM 
dCTP( lOmM) 1.25 0.5 mM 
dGTP (10 mM) 1.25 0.5 mM 
AmpliTaq Gold® DNA 0.3 0.06 尋L 
Polymerase (5 U/|xL) 
Forward Primer (10 _ 1 0.4 |xM 
Reverse Primer (10 }xM) 1 0.4 |iM 
DNA sample 2 -
Total 25 -
(B) Thermal profile of initial PCR 
Step Temperature Time 
AmpliTaq Gold® activation 95 5 min 
Denaturation 95 30 s 
45 cycles Annealing 62 °C 30 s 
Extension 72 °C 30 s 
Final incubation 72 °C 7 min 
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Table 3.4 Shrimp Alkaline Phosphatase (SAP) treatment. 
(A) Composition of SAP reaction mixture (Sequenom) 
Component Volume for one reaction (^L) 
MassARRAY™ SAP buffer 0.34 
SAP 0.6 
Deionised water 3.06 
PCR product ^ 
Total 29 
(B) Thermal profile of SAP treatment 
Step Temperature Time 
Activate SAP 37 40 min 
SAP deactivation 85 °C 5 min 
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Table 3.5 iPLEX® Gold single base primer extension reactions. 
(A) Composition of iPLEX® Gold reaction mixture (Sequenom) 
Component Volume for one Final concentration reaction (^L) 
Deionised water 1.7585 -
iPLEX Buffer Plus (lOx) 0.3 0.22X 
ddATP (40 mM) 0.075 0.22 mM 
ddTTP (40 mM) 0.075 0.22 mM 
ddCTP (40 mM) 0.075 0.22 mM 
ddGTP (40 mM) 0.075 0.22 mM 
Extension primer (10 |iM) 1.08 0.8 [iU 
iPLEX Enzyme (220x) 0.0615 1X 
SAP-treated PGR product ： 
Total 13.5 -
(B) Thermal profile of iPLEX® Gold reaction 
Step Temperature Time 
Denaturation 94 30 s 
‘ Denaturation 9 4 � C 5 s 
40 cycles s � Annealing 52 °C 5 s 5 cycles i . „ � [ Extension 80 C 5 s 
Final extension 72 °C 3 min 
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3.5.2 Multiplex paralogous sequence assay 
The multiplex paralogous sequence assay was used for targeting multiple pairs of 
paralogous sequences, so that more template molecules could be counted and less 
volume of maternal blood sample would be needed for analysis. The main difference 
between monoplex and multiplex assay is that the multiplex assay targets four pairs 
of paralogous sequences on chr21 and four other reference non-trisomic 
chromosomes, namely chromosomes 1, 2, 6 and 7. Four pairs of common forward 
and reverse primers were used. The principle of detecting different PSMs on different 
chromosomes by MALDI-TOF MS is the same. The individual assays were designed 
such that the extension primer and products of each assay have unique masses. They 
could then be resolved by mass spectrometry, giving eight extension product peaks in 
the mass spectrum. Dosage of chr21 can then be determined with reference to the 
four non-trisomic chromosomes. 
The preparation of the initial PCR reaction mixture in multiplex assay is summarised 
in Table 3.6 A. The components in the reaction mixture were basically the same as 
that in the corresponding monoplex version of the assay, except that for each forward 
and reverse primer, only one-fourth of the volume as in the monoplex assays, i.e., 
0.25 \iL was added. The thermal profile of the initial PCR reaction was also the same 
as that in the monoplex assays. 
SAP treatment was set up to deactivate the unincorporated dNTPs in the PCR 
product. The same treatment mixture and thermal profile as in the monoplex assays 
were employed. 
The iPLEX® Gold reaction was set up for single base primer extension. Table 3.6 B 
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summarises the preparation of the iPLEX® Gold reaction mixture, with some 
adjustments compared to that in the monoplex assays. Since there are four individual 
assays in the multiplex assay, they would compete for resources like the 
dideoxyribonucleotides (ddNTPs) in the termination mix, leading to lower extension 
peak intensities. To avoid this, more than double the amount of termination mix was 
added to the reaction mixture. The total amount of all extension primers added was 
also doubled. The extension primer of the highest-mass assay, PV2106_L, was 
diluted to 30 ja.M, instead of the usual 10 |iM for the other assays. The same thermal 
profile as in the monoplex assays was employed. 
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Table 3.6 Multiplex PV2101/PV2107a/PV2102b/PV2106_L assay. 
(A) Composition of initial PCR mixture (AmpliTaq Gold® DNA polymerase, Applied 
Biosystems) 
^ ^ Volume for one , • Component , T� Final concentration reaction (^ iL) 
Deionised water 9.775 -
lOx PCR buffer II 3.125 1.25X 
MgCl2 (25 mM) 2.8 2.8 mM 
dATP (10 mM) 1.25 0.5 mM 
dTTP (10 mM) 1.25 0.5 mM 
dCTP (10 mM) 1.25 0.5 mM 
dGTP (10 mM) 1.25 0.5 mM 
AmpliTaq Gold® DNA o.3 0.06 U/^L 
Polymerase (5 U/|LIL) 
PV2101 Forward Primer (10 |iM) 0.25 0.1 |LIM 
PV2107a Forward Primer (10 |xM) 0.25 0.1 |iM 
PV2102b Forward Primer (10 _ 0.25 0.1 |iM 
PV2106_L Forward Primer (10 |LIM) 0.25 0.1 \iM 
PV2101 Reverse Primer (10 |iM) 0.25 0.1 |iM 
PV2107a Reverse Primer (10 jiM) 0.25 0.1 [M 
PV2102b Reverse Primer (10 _ 0.25 0.1 i^ M 
PV2106_L Reverse Primer (10|LIM) 0.25 0.1 i^M 
DNA sample 2 -
Total 25 -
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(B) Composition of iPLEX® Gold reaction mixture (Sequenom) 
_ Volume for one ， , Component , , � Final concentration reaction (^ iL) 
Deionised water 0.3285 -
iPLEX Buffer Plus (lOx) 0.3 0.22X 
ddATP (40 mM) 0.1625 0.48 mM 
ddTTP (40 mM) 0.1625 0.48 mM 
ddCTP (40 mM) 0.1625 0.48 mM 
ddGTP (40 mM) 0.1625 0.48 mM 
PV2101 Extension primer (10 |IM) 0.54 0.4 |LIM 
PV2107a Extension primer (10|LIM) 0.54 0.4 [M 
PV2102b Extension primer (10 |xM) 0.54 0.4 i^M 
PV2106_L Extension primer (30 |LIM) 0.54 1.2 mM 
iPLEX Enzyme (220x) 0.0615 Ix 
SAP-treated PCR product 10 ： 
Total 13.5 - — 
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3.6 Digital PCR 
3.6.1 Principle 
In digital PCR, the extracted DNA is diluted to an extremely low concentration such 
that there is no more than one template molecule per reaction well on average. After 
distributing the DNA molecules into the wells of 3 84-well reaction plates, a 
multitude of PCRs are set up (Lo et al 2007a). Under such conditions, most positive 
amplifications would represent signals from a single template molecule (Vogelstein 
and Kinzler 1999). The number of wells giving positive signals would correspond to 
the number of DNA template molecules present in the original sample (Fan and 
Quake 2007). Since the amount of DNA in the samples is quantified by counting 
amplifications from single molecules, digital PCR has the advantage that it allows a 
much greater precision of measurement than quantitative real-time PCR. Also, unlike 
real-time PCR, digital PCR is not sensitive to fluctuations in amplification efficiency, 
again leading to a more precise DNA quantification (Fan and Quake 2007). One 
other advantage is that digital PCR does not depend on the use of calibration 
standards for sample DNA quantification, while real-time PCR does. Thus, DNA 
quantification by digital PCR would not be affected by inaccuracies due to variations 
in calibrators that may exist between batches and laboratories (Zimmermann et al 
2005). 
3.6.2 Digital multiplex paralogous sequence assay 
The same four pairs of paralogous sequences on chr21 and the four reference 
chromosomes were amplified in multiplex fashion, and analysed by MALDI-TOF 
MS. The dosage of chr21 can then be determined by counting the number of 
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molecules of chr21 in relation to any of the four non-trisomic reference 
chromosomes. 
The total reaction volume in the initial PCR was 5 \iL, and the AmpliTaq Gold® DNA 
Polymerase (Applied Biosystems, Foster City, CA) was used. The extracted 
placental/matemal blood cell DNA was quantified by spectrophotometry (NanoDrop 
Technologies, Wilmington, DE) and then serially diluted. I aimed at a DNA 
concentration of 1 template molecule per reaction well in the dilution. Since the 
multiplex assay comprises of four individual monoplex assays, there would be eight 
potential amplicons in a diploid genome. Therefore, 1 template molecule refers to 
any one of these potential amplicons, and the aim of dilution would be 1/16 of a GE 
per well. The preparation of the initial PCR mixture is summarised in Table 3.7 A. 
The volumes of all components in the mixture were scaled down to a total volume of 
5 |aL. The same thermal profile as in the monoplex assays was employed. 
SAP treatment was set up to deactivate the unincorporated dNTPs in the PCR 
product. Table 3.7 B summarises the preparation of the SAP reaction mixture. Again, 
the volumes of all components in the mixture were scaled down, and the same 
thermal profile was used. 
The iPLEX® Gold reaction was set up for single base primer extension. Table 3.7 C 
summarises the preparation of the iPLEX® Gold reaction mixture, with all volumes 
scaled down. The same thermal profile was used. After that, 16 [iL of water and 6 mg 
of SpectroCLEAN Resin (Sequenom) were added for cleaning up the final extension 
products. Mass spectra acquisition and data analysis were done. 
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Table 3.7 Digital multiplex PV2101/PV2107a/PV2102b/PV2106_L assay. 
(A) Composition of initial PCR mixture (AmpliTaq Gold® DNA polymerase, Applied 
Biosystems) 
Component Volu?e for one Final concentration reaction (^ iL) 
Deionised water 2.255 -
lOx PCR buffer II 0.625 1.25X 
MgCl2 (25 mM) 0.56 2.8 mM 
dATP (10 mM) 0.25 0.5 mM 
dTTP (10 mM) 0.25 0.5 mM 
dCTP(lOmM) 0.25 0.5 mM 
dGTP (10 mM) 0.25 0.5 mM 
® AmpliTaq Gold DNA 0.06 0.06 U尔L 
Polymerase (5 U/jiL) 
PV2101 Forward Primer (10 gM) 0.05 0.1 i^M 
PV2107a Forward Primer (10 |LIM) 0.05 0.1 i^M 
PV2102b Forward Primer (10 ^M) 0.05 0.1 \M 
PV2106一L Forward Primer (10 i^M) 0.05 0.1 |xM 
PV2101 Reverse Primer (10 ^M) 0.05 0.1 i^M 
PV2107a Reverse Primer (10 \M) 0.05 0.1 |LIM 
PV2102b Reverse Primer (10|aM) 0.05 0.1 |iM 
PV2106一L Reverse Primer (10 |iM) 0.05 0.1 |iM 
DNA sample 0.1 -
Total 5 ； 
(B) Composition of SAP reaction mixture (Sequenom) 
Component Volume for one reaction (^ iL) 
MassARRAY™ SAP buffer 0.17 
SAP 0.3 
Deionised water 1.53 
PCR product 5 
Total 7 
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(C) Composition of iPLEX® Gold reaction mixture (Sequenom) 
Volume for one . • Component reaction (^ iL) Final concentration 
Deionised water 0.1877 -
iPLEX Buffer Plus (lOx) 0.1714 0.19X 
ddATP (40 mM) 0.09285 0.41 mM 
ddTTP (40 mM) 0.09285 0.41 mM 
ddCTP (40 mM) 0.09285 0.41 mM 
ddGTP (40 mM) 0.09285 0.41 mM 
PV2101 Extension primer (10 i^M) 0.3086 0.34 |iM 
PV2107a Extension primer (10 |iM) 0.3086 0.34 i^M 
PV2102b Extension primer (10 i^M) 0.3086 0.34 |xM 
PV2106一L Extension primer (30 |iM) 0.3086 1.03 |iM 
iPLEX Enzyme (220x) 0.03514 0.86X 
SAP-treated PGR product 7 ： 
Total 9 ： 
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Anticontamination measures 
To prevent PGR contamination, strict precautions were taken. Aerosol-resistant 
pipette tips were used for all liquid handling. Separate areas were used for DNA 
extraction, setting up of amplification reactions, addition of DNA template, and 
carrying out of amplification reactions. Multiple negative water blanks were included 
in every analysis (Lo et al 1998). 
3.7 Statistical analysis 
3.7.1 Disease classification of samples 
For the prenatal diagnosis of fetal trisomy 21, a change in the ratio of chr21 to the 
reference chromosome from 2:2 in a euploid fetus to 3:2 in a T21 fetus has to be 
differentiated. However, for non-invasive prenatal diagnosis through fetal DNA 
analysis in maternal plasma, the degree of chr21 overrepresentation is diluted. Since 
fetal DNA is present in a high background of maternal DNA in the maternal plasma, 
the degree of chr21 overrepresentation would depend on the fractional fetal DNA 
concentration. For instance, at 10% fetal DNA concentration, the amount of 
chr21-derived sequences of a T21 pregnancy would be 1.05 times that of a euploid 
case (Lo et al 2007a). Therefore, for disease classification of various samples, 
statistical analysis is needed. 
3.7.2 Poisson distribution 
As mentioned, the number of positive wells in a digital run corresponds to the 
number of template molecules in the original sample. However, the actual number of 
template molecules distributed to each reaction well follows the Poisson distribution. 
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The Poisson equation is given as follows: 
Pin) 二 — 
n\ 
where n is the number of template molecules per well, P{n) is the probability of n 
template molecules in a particular well, and m is the average number of template 
molecules in a particular digital PCR experiment. After a digital PCR run, an 
individual reaction well could have zero, one, or more template molecules. The 
expected proportion of wells with no template, i.e.，P(0), is given by e~"\ where m is 
the average concentration of template molecules per well. For example, at an average 
concentration of one template molecule per well, the expected proportion of wells 
with no template molecule is given by i.e., 0.37 (37%). The remaining 63% of 
wells will contain one or more template molecules (Lo et al 2007a). Therefore it can 
be confirmed that the PCR run operates at digital level when approximately 37% of 
the wells show negative amplification. 
The actual template concentration could be derived from the Poisson equation. 
Typically, after a digital PCR run, the number of positive wells for each amplicon in 
the multiplex assay would be counted. However, since each positive well may 
contain one or more template molecules, the actual number of template molecules 
would be greater than the number of positive wells for each amplicon, according to 
Poisson distribution. To determine the actual template concentration, the 
Poisson-corrected count needs to be calculated from the number of positive wells. 
This is illustrated as follows. 
In a digital PCR run on a 384-well plate, assuming that the number of wells positive 
for a certain locus is 45. The Poisson equation, as discussed above, is: 
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� m"e-m Pin) = ^ — n\ 
The expected proportion of wells with no template, i.e. P(0) = e"'" 
(total no. of wells - no. of positive wells)/total no. of wells = e"'" 
m = -In [(total no. of wells - no. of positive wells)/total no. of wells] 
= -ln [(384-45)7384]-0.125 
Since m is the average concentration of template molecules per well, the 
Poisson-corrected count would be: 
0.125*384 = 48 
which is the actual number of template molecules for the locus. 
Therefore, according to Poisson distribution, the actual number of template 
molecules of a certain locus can be calculated by: 
L = -In [(N-/)/N]*N 
where L is the number of template molecules of the locus, N is the total number of 
wells counted, and I is the number of wells positive for the locus. 
3.7.3 Data analysis 
After the digital PCR run, the wells giving uncertain calls were manually corrected. 
The bad spectra, as called by the TyperAnalyzerFS software (Sequenom) and were 
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usually without any extension product peaks or primer peaks, were either corrected 
or discarded. The numbers of wells positive for chr21 or the reference chromosome 
for each of the four assays were then independently scored. For each assay, the 
Poisson-corrected numbers of molecules for chr21 and the reference chromosome 
were calculated. The sum of the Poisson-corrected number of molecules for chr21 as 
well as the sum of the Poisson-corrected number of reference chromosomes from all 
four assays were calculated and deemed as the combined informative counts for the 
4-plex assay. The Pr value, the proportion of the overrepresented chromosome, i.e., 
chr21, among all informative counts (Lo et al 2007a), was calculated by dividing the 
chr21 informative count for the 4-plex assay by the sum of the chr21 and reference 
chromosome informative counts for the 4-plex assay. The experimentally derived Pr 
value was then subjected to the sequential probability ratio test (SPRT) analysis for 
disease classification. One or more 384-well plates would be analysed until disease 
classification was possible by SPRT (Lo et al. 2007a; Zhou et al. 2001). 
3.7.4 Sequential probability ratio test (SPRT) analysis 
To determine whether the degree of overrepresentation of chr21 was statistically 
significant, the SPRT analysis was employed. SPRT allows testing of two hypotheses, 
the null and the alternative hypotheses. Testing of the hypotheses can be conducted 
while data accumulate. For the detection of fetal trisomy 21，the null hypothesis is 
that there is no chromosomal imbalance, whereas the alternative hypothesis is that 
chromosomal imbalance is present. Acceptance of the null hypothesis would lead to 
the classification of a case as euploid while acceptance of the alternative hypothesis 
would lead to the classification of a case as trisomy 21. Alternatively, neither the null 
nor alternative hypothesis could be accepted if the Pr for the given number of 
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informative counts has not yet reached the required level of statistical confidence for 
disease classification. These cases are deemed unclassifiable until more data are 
available. 
SPRT operates with a pair of SPRT curves which define the probabilistic boundaries 
for accepting or rejecting the null and the alternative hypotheses. These curves show 
the required proportion of informative counts positive for the chr21, P^ {y axis, 
Figure 3.2), for a given total number of informative counts (x axis, Figure 3.2) 
needed for disease classification. Samples with data points above the top curve are 
classified as trisomic, while those with data points below the bottom curve are 
classified as euploid (Figure 3.2). Samples with data points in between the two 
curves are unclassifiable and would require a greater total number of informative 
counts before disease classification. 
The advantage of SPRT analysis is that a smaller amount of testing is required for a 
given level of confidence compared to other statistical methods. Since the number of 
available template molecules is limited in our samples, this feature is of particular 
relevance in this study (Lo et al. 2007a). 
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Figure 3.2 Sequential Probability Ratio Test analysis. A pair of SPRT curves 
delimits the probabilistic boundaries for accepting or rejecting the null and the 
alternative hypotheses. Samples with data points above the top curve are classified as 
trisomic, while those with data points below the bottom curve are classified as 
euploid. Samples with data points in between the two curves are unclassifiable and 
would require a greater total number of informative counts before disease 
classification. 
(Adapted and modified from Figure 2A, Lo et al. 2007) 
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Concluding remark 
This chapter describes the principle of MALDI-TOF MS, optimised protocols of 
monoplex paralogous sequence assays, multiplex paralogous sequence assay and 
digital multiplex paralogous sequence assay used for the detection of fetal trisomy 21. 
The SPRT analysis used for disease classification is also explained. 
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CHAPTER 4: TESTING OF ASSAY SPECIFICITY WITH 
CORIELL CELL LINES 
4.1 Coriell cell lines 
The Coriell Cell Repositories from the Coriell Institute for Medical Research is a 
provider of biological and research reagents to research scientists around the world. 
They establish, verify, maintain and distribute cells cultures and DNA derived from 
cell cultures. Among their collections, the NIGMS Human Genetic Cell Repository 
provides samples including highly characterised cell lines and high quality DNA. In 
our experiments, the Mapping Panel #2 of the Human/Rodent Somatic Cell Hybrids 
was employed. Mapping Panel #2 consists of DNA isolated from 24 human/rodent 
somatic cell hybrids. The human parent and rodent parent of each hybrid are 
summarised in Table 4.1. All of the hybrids retain a single intact human chromosome. 
These cell hybrids allow us to test the specificity of the initial PCR primers and the 
iPLEX® Gold extension primers to see if they only give signals from the human 
chromosomes targeted in the paralogous sequence assays. This is essential as I have 
to ensure that the assays are specific before applying on clinical samples. 
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Table 4.1 The human parent and rodent parent of 24 human/rodent somatic cell 
hybrids. 
Human Chromosomes Present Hybrid DNA Human Parent Rodent Parent 
1 NA13139 MRC5 Mouse 
2 NA10826 Chinese Hamster 
3 NA 10253 Chinese Hamster 
4 NA10115 Chinese Hamster 
5 NA10114 Chinese Hamster 
6 NA11580 Chinese Hamster 
7 NA10791 Chinese Hamster 
8 NA10156 Chinese Hamster 
9 NA10611 GM07890 Mouse 
10 NA 10926 Chinese Hamster 
11 NA10927 Chinese Hamster 
12 NA10868 GM07890 Chinese Hamster 
13 NA10898 Chinese Hamster 
14 NA11535 Chinese Hamster 
15 NA11418 Chinese Hamster 
16 NA10567 GM02860 Mouse 
17 NA10498 GM00271 Mouse 
18 NAllOlO Chinese Hamster 
19 NA 10449 Chinese Hamster 
20 NA13140 MRC5 Mouse 
21 NA10323 AG06814 Mouse 
22 NA10888 Chinese Hamster 
X NA06318 Chinese Hamster 
Y NA06317 Chinese Hamster 
Parental DNA^ Description 
NAIMR91 Human Line IMR91 
NAOS 862 Mouse Line 3T6 
NA10658 Chinese Hamster Line RJK88 
a The human line, mouse line and the Chinese hamster line used for constructing the 
somatic cell hybrids above, unless otherwise stated for the human parent. 
Adapted from website of Coriell Cell Repositories. 
(http://ccr.coriell.org/Sections/Collections/NIGMS/Map02.aspx?PgId=496) 
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4.2 Specificity of initial PCR primers 
4.2.1 Principle 
To check the specificity of the initial PCR primers, the initial PCRs were performed 
with all pairs of initial primers under investigation, with DNA samples extracted 
from the Coriell cell lines added as the template. The initial PCRs were performed in 
non-digital monoplex manner, with only one human chromosome present in each 
reaction. DNA samples from the whole panel of cell line as shown in Table 4.1 were 
screened for each pair of initial PCR primers. After the reaction, the PCR products 
were analysed by agarose gel electrophoresis. If a certain pair of initial PCR primers 
is specific, it should only amplify human chr21 and one other human reference 
chromosome on which the paralogous partner is located, so bands should only be 
observed for the wells containing human chr21 and the other target human reference 
chromosome, but not the others. Otherwise, the pair of initial PCR primers is 
non-specific. 
4.2.2 Materials and methods 
The initial PCRs were performed according to the initial PCR mixture in Table 3.3 A 
and the thermal profile in Table 3.3 B. The initial pairs of primers tested are listed in 
Table 4.2. In each reaction well, only one pair of forward and reverse PCR primer 
was tested with hybrid cell DNA containing one human chromosome as the DNA 
template. Each primer pair was tested with human chromosomes 1-22，X and Y as 
the DNA template. Mouse cell DNA and Chinese hamster ovary cell (CHO cell) 
DNA without human chromosome were also used as templates. The PCR products 
were analysed by gel electrophoresis on a 2% agarose gel. In each well, 5 |iL of PCR 
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products and 1 |iL of Blue/Orange 6X Loading Dye (Promega, U.S.A.) were loaded. 
The 100 bp DNA Step Ladder (Promega, U.S.A.) was used. The agarose gel was 
stained by GelRed™ (Biotium, U.S.A) and image capturing was done by the 
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4.2.3 Results 
M l 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 X Y M U C 
i o o b p ~ i y H H 9 H R H B H R B I B B B I O 
PV2117 assay 
M l 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 X Y M U c 
1 0 0 b p i H 
PV2106 assay [ , 丄 T ：： ’ 八 < ] [ ‘ ‘ 4 c ‘ j 
M I 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 X Y M U C 
m m ^ ^ m m m m a m m a ^ m a i L B I ^ H I 
PV2107b assay ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ 
M l 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 X Y M y c 
100 bp 
• i I 
PV2115 assay • H H H H H H H H H ^ ^ H H H ^ H H ^ B i 
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 X Y M U C 
loo t 邏 
PV2113 assay H H I ^ H ^ H ^ H H I ^ H H I ^ H H H H H i H l 
M l 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 X Y M U C 
PV2101 assay • • ^ • • H H ^ H H I I I H I • • • • • • • 
M l 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 X Y M U C 
100 | f t » 
PV2107a assay ^ H I ^ ^ ^ H I H ^ H H H ^ ^ H ^ H H I 
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 X Y M U C 
loo v g 
PV2105 assay • • • • • • • • • • • • • ^ ^ H • ^ ^ • I ^ B l 
M l 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 X Y M U C 
ZFY/X assay100 3 9 B 8 
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 IS 16 17 18 19 20 21 22 X Y M U C 
100 bp-B 
PV2102a assay H H H H I H H H H H ^ H i i l i H H I H H H H S H H 
M l 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 X Y M U C 
PV2102c assay I'二 ‘‘ ‘ ^ '八‘二、• �二、 ‘ � " �丨叙：、 ^ ^ 
M l 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 X Y M v c 
I J ^ ^ H H H H i i H I 9 H H 
PV2102b assay 丨 
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Figure 4.1 PCR amplification results with various initial PCR primers with the 
Coriell cell line panel. Out of a total of 14 paralogous sequence assays, 12 are 
shown here. PV2106 assay targeted the same paralogous sequences and PSM as 
PV2106_L assay, and had the same pair of forward and reverse PCR primer. PV2106 
was the initial assay name before the optimisation process. In the figures, M denotes 
the 100 bp DNA Step Ladder (Promega, U.S.A.). On top of each well, 1-22, X and Y 
denote the human chromosome present as the DNA template (on the left gel panel). 
U and C denote the mouse cell DNA only template and CHO cell DNA only template, 
respectively (on the right gel panel). 
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Results 
In the above figure, PV2106 assay, PV2101 assay, ZFY/X assay and PV2102b assay 
showed only 2 bright DNA bands when human chromosomes 1-22, X and Y were 
used as the DNA templates, while no bands were observed when mouse cell DNA 
only and CHO cell DNA only were used as templates. These results demonstrate that 
for the assays PV2106, PV2101, ZFY/X and PV2102b, the initial PCR primers 
amplify only human chr21 and the human reference chromosome, but not other 
chromosomes in the human genome. These pairs of initial PCR primers are therefore 
specific primers. 
For assays PV2117, PV2107b, PV2107a, PV2105, PV2102a and PV2102c, a number 
of bands could be observed when human chromosomes 1-22，X and Y were used as 
the DNA templates. However, bands were also observed when mouse cell DNA only 
and CHO cell DNA only were used as templates. These results demonstrate that the 
initial PCR primers of these assays amplify mouse cell DNA, CHO cell DNA or even 
both. Since the Coriell cell lines consist of somatic cell hybrids between mouse/CHO 
cell and human cell, I do not know whether the initial PCR primers amplified more 
than 2 human chromosomes, or they amplified the mouse cell or CHO cell DNA. The 
specificity of these initial PCR primers cannot be concluded. 
For assays PV2115 and PV2113，a number of bands could be observed when human 
chromosomes 1-22, X and Y were used as the DNA templates, while no bands were 
observed when mouse cell DNA only and CHO cell DNA only were used as 
templates. The initial PCR primers of these assays amplify not only human chr21 and 
the human reference chromosome, but also other human chromosomes. These initial 
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PCR primers are therefore non-specific. 
4.2.4 Conclusion 
With this initial check with the Coriell cell lines, only assays PV2106, PV2101, 
ZFY/X and PV2102b were found to be specific. Therefore only these assays were 
tested in the next phase. 
4.3 Specificity of the iPLEX® Gold extension primers 
4.3.1 Principle 
To check the specificity of the iPLEX® Gold extension primers, I investigated 
whether the extension primers can distinguish between human chr21 and the human 
reference chromosome of each paralogous pair. In other words, I looked at whether 
only the corresponding extension product peak is observed when only one human 
chromosome is present as the DNA template. This would confirm that the iPLEX 
assays are effective in distinguishing the paralogous pairs through the PSMs. I 
performed non-digital monoplex assays using DNA samples from the Coriell cell 
lines as templates. In each reaction well, either human chr21 or human reference 
chromosome was present as the template. After MALDI-TOF MS analysis, if the 
iPLEX® Gold extension primer is specific, just the chr21 peak would be observed 
with human chr21 only as the template, while just the reference chromosome peak 
would be observed with human reference chromosome only as the template. 
Otherwise, if more than one peak is observed, the iPLEX® Gold extension primer is 
non-specific. 
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4.3.2 Materials and methods 
Non-digital monoplex PCR reaction was performed according to the reaction mixture 
in Table 3.3 A and the thermal profile in Table 3.3 B. Based on the initial specificity 
test, only the extension primers of PV2101, PV2102b and PV2106—L assays were 
tested. 
DNA samples from the Coriell cell lines were used. For the PV2101 assay, either 
human chr21 or human chrl was included as the template. For the PV2102b assay, 
either human chr21 or human chr2 was included as the template. For the PV2106—L 
assay, either human chr21 or human chr6 was included as the template. 
Quadruplicate reactions were set up per assay per template. Triplicate control 
reactions with no template were also set up per assay. SAP treatment and iPLEX® 
Gold single base primer extension reactions were done as in Tables 3.4 and 3.5, 
followed by MALDI-TOF MS analysis. 
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4.3.3 Results 
(A) PV2101 assay 
DNA template: human chromosome 21 
UEP chr21 chrl 
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DNA template: human chromosome 1 
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(B) PV2102b assay 
DNA template: human chromosome 21 
UEP chr2 chr21 
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DNA template: human chromosome 2 
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(C) PV2106_L assay 
DNA template: human chromosome 21 
UEP chr21 chr6 
1 n 1 
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I - 丨 M i 
� - 1 I I 1 r r r r r r r A r j i i i i ^ h T T T T r ^ y V l ^ r T f T r ^ r T r r i m u 
7500 7600 7700 7800 7900 8000 8100 8200 8300 8400 
Mass 
DNA template: human chromosome 6 
UEP chr21 chr6 
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Figure 4.2 Mass spectra showing the specificity of the iPLEX® Gold extension 
primers of (A) PV2101 assay, (B) PV2102b assay and (C) PV2106_L assay. 
Either chr21 or the reference chromosome in each assay was added as the template 
using samples from the Coriell cell lines. In each spectrum, the x-axis depicts the 
molecular mass of the ions and the 少-axis depicts the intensity in arbitrary units. UEP 
denotes the unextended primer. Only one spectrum from the quadruplicate reactions 
per assay per template is shown here. 
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Results 
Figure 4.2 shows that for all three assays, namely PV2101, PV2102b and PV2106_L 
assays, when only chr21 was present as the DNA template, a single chr21 peak was 
observed, whereas when only the reference chromosome was present, a single 
reference chromosome peak was observed. Consistent results were obtained from the 
quadruplicate reactions, while no signal was detected from the control reactions with 
no template. Therefore the iPLEX® Gold extension primers of PV2101, PV2102b 
and PV2106 L assays are specific. 
4.4 Further analysis on the specificity of PV2107a initial PCR primers 
Since bands were observed for PV2107a assay for almost the entire human 
chromosome panel, and also the mouse cell DNA only and CHO cell DNA only 
templates in Figure 4.1，to justify the inclusion of this assay in the multiplex 
paralogous sequence assay, the specificity of PV2107a initial PCR primers was 
further analysed with the initial PCR products obtained. If the PV2107a initial PCR 
primers are specific, bands should only be observed for human chromosomes 21 and 
7，so all the other bands should be due to amplifications from the mouse cell or CHO 
cell DNA. To test this hypothesis, the initial PCR products from the entire human 
chromosome panel were SAP treated, and iPLEX® Gold single base primer extension 
reactions were performed. After MALDI-TOF MS analysis, the results showed that 
just the chr7 peak was observed for all PCR products obtained except when human 
chr21 was used as the template, which gave a non-polymorphic call positive just for 
the Coriell cell line containing the human chr21. At the same time, I performed an 
In-Silico PCR search with the PV2107a initial PCR primers on the UCSC genome 
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browser. I then performed a BLAT search for the human chr21 amplicon against the 
mouse genome. The results are shown in Figure 4.3. 
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A. UCSC In-Silico PCR (Genome: Human) (Assembly: Feb 2009) 
>chr21:26058862+26058963 102bp 
AOnTGGATGGMTTTMGCTAAATCAGCCTGAACTG ACGTTGGATGGnTCTCATAGTTCATCGTAGGCTTAT 
t gaTgaagg tGMTITMGOAMTCAGCCTGAACrGg t tgcacagaaat fiLAT 





t gaTaaagg tGMTTTMGCTMATCAGCCTGMCTGg 11 gcacaaaaa t 
ggggacagcgtaaaaATAAGCCTAOjATGAACTATGAGAAACt cagtegt 
Gc 
g/a - PSMs 
B. Alignment ofYourSeq and chrl6:84857710-84857802 
cDNA YourSeq 
TGATGAAGGT GMTTTAAGC TAAATCAGCC TGAacTGGTT GCaCAgAAAT 50 
GGGGACAgCG TAAaAAtAAG CCTACgATGA ACTATGAGAA ACTcagtcgt 100 
gc 
Genomic chrl6: (Genome: mouse) (Assembly: July 2007) 
tgc t tacgga t t t aggaaac aatggtcaga t c caac t a tg g c a g t t t t t g 84857659 
c t a g a a c t t c t t ac tgacaa ggatgetega g a c t g t a t t t c t t g g g t t g g 84857709 
TGATGAAGGT GMTTTAAGC TAAATCAGCC TGAgtTGGTT GCgCAaAAAT 84857759 
GGGGACAaCG TAAgAAcAAG CCTACcATGA ACTATGAGAA ACTtagccgt 84857809 
gea t t aegg t a a g a a t t t g t t t t t t g t t t t c t a a t a t c a t a c t t c t c t a g 84857859 
aaa tg tagc t t c t t a t t c t t ga ta taaacc t g g t a g t t a a tga 
Side by Side Alignment 
00000001 tga tgaagg tgaa t t t aagc taaa t cagcc tgaac tgg t tgcacagaaa t 00000050 
» » » » I I I I I M I I I I I I M I M I I I I M M M I I I I I l l l l l l l II MM » » » » 
84857710 tgatgaaggtgaat t t aagc taaa tcagcc tgag t tgg t tgcgcaaaaa t 84857759 
00000051 ggggacagcgtaaaaataagcctacgatgaacta tgagaaact 00000093 
» » » » I j j丨丨丨I M i l l 11 MINIM丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨I » » » » 
84857760 ggggacaacgtaagaacaagcctaccatgaacta tgagaaact 84857802 
69 
Testing of assay specificity 
Figure 4.3 In-Silico PCR and BLAT search analysis on UCSC genome browser 
for PV2107a assay. In-Silico PCR was performed with the PV2107a forward and 
reverse initial PCR primers. The sequence amplified on human chr21 (shaded part in 
panel A) was then analysed by BLAT search against the mouse genome. Coloured in 
blue in panel B are the matching bases between the human chr21 and the mouse 
genomic sequences, while light blue bases mark the boundaries of gaps in either 
sequence. Coloured in red are the PSMs in both human and mouse genomic 
sequences. 
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As seen in Figure 4.3，the PSMs in mouse genomic chrl6 and human chr7 have the 
same base A. This is consistent with the hypothesis and can explain why just the chr7 
peak was obtained for almost the entire human chromosome panel. However, the 
same analysis cannot be done on CHO cell genome as the CHO cell genomic 
database is not yet available. Nevertheless, this analysis supported the hypothesis that 
the bands observed were due to amplifications from the background DNA, instead of 
the human chromosomes present. 
4.5 Conclusion 
In conclusion, for the paralogous sequence assays, the initial PCR primers of 
PV2106 assay, PV2101 assay, ZFY/X assay and PV2102b assay are specific primers, 
while the iPLEX® Gold extension primers of PV2101 assay, PV2102b assay and 
PV2106—L assay are also specific primers. From Chapter 4.4，further analysis 
showed that the initial PCR primers of PV2107a assay should also be specific and 
allowed this assay to be used. Therefore, PV2107a assay was included in our further 
development of the multiplex assay. To summarise, the assays selected for the next 
step are PV2101, PV2107a, PV2102b and PV2106—L assays. 
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CHAPTER 5: ASSAY OPTIMISATION 
5.1 Introduction 
Since the paralogous sequence assays involve several steps, i.e., the initial PCR 
reaction, SAP treatment and the single base primer extension reaction, various 
parameters have to be optimised before coming up with final assay protocols and 
conditions. Parameters that could be optimised include the annealing temperature and 
magnesium ion concentration in the initial PCR reaction, extension primer 
concentration in the single base primer extension reaction and so on. Besides, the 
optimisation process is further complicated by the fact that I was aiming to multiplex 
the selected paralogous assays. In this chapter, a step-by-step introduction of the 
whole process of assay optimisation until the final assay protocols and conditions are 
achieved. The aim of optimisation is to develop a multiplex paralogous assay that is 
specific, has the highest multiplexing level possible, and most importantly, can 
clearly differentiate between euploid and T21 samples (Deutsch et al. 2004). 
5.2 Optimisation of initial PCRs with AmpliTaq Gold® DNA polymerase 
followed by homogeneous MassEXTEND™ (hME) assays (Sequenom) 
5.2.1 Optimisation of initial PCR reactions 
The initial PCR reactions were first performed using AmpliTaq Gold® DNA 
polymerase. Three annealing temperatures (Ta) were tested on 1 normal placental 
DNA sample with 8 paralogous sequence assays as summarised in Table 5.1. The 3 














































































































































































































































































































































































































































































































































































































































































































































































































The resulting PCR products were analysed by gel electrophoresis. Figure 5.1 shows 
the results. 
T a = 60 °C 62 °C 57 °C 
Figure 5.1 PCR amplification products from initial PCRs with 3 annealing 
temperatures: 57 °C, 60 °C and 62 0C. In the figure, M denotes the 100 bp DNA 
Step Ladder (Promega, U.S.A.). On top of each well, 1-8 denote the 8 paralogous 
sequence assays shown in Table 5.1: 1 denotes PV2102c assay, 2 denotes PV2118 
assay, 3 denotes PV2115 assay, 4 denotes PV2106 assay, 5 denotes PV2107b assay, 6 
denotes PV2107a assay, 7 denotes PV2102d assay and 8 denotes ZFY/X assay. Top 
panel: normal placental DNA template. Bottom panel: no template controls. 
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Bright single DNA product bands were observed for all 3 annealing temperatures 
tested, indicating that specific PCR products were produced at annealing 
temperatures 57 °C, 60 °C and 62 °C for all assays except PV2102d assay, which 
gave double bands at Ta = 57 °C and 60 °C. The formation of these secondary bands 
may be due to sequence mismatch tolerance or the formation of secondary primer 
structures, such as hairpins or dimers (Devor et al.). Since this assay gave 
non-specific PCR products at Ta = 57 °C and 60 °C, and its negative controls gave 
positive signals at all 3 annealing temperatures, it was considered to have 
assay-specific problems and was thus not considered further for ultimate inclusion in 
the multiplex assay. The optimal annealing temperature was determined to be 62 °C 
since it gave the most specific PCR products and the negative controls gave cleanest 
results. 
5.2.2 Principle of homogeneous MassEXTEND™ assays (Sequenom) 
Homogeneous MassEXTEND™ assay is used in SNP genotyping. The principle of 
hME assay is very much similar to that of MassARRAY® iPLEX Gold assay 
(Sequenom). Basically, after the initial PCR reaction and SAP treatment, single base 
primer extension is performed, in which extension products of different masses are 
produced and differentiated by MALDI-TOF MS analysis. However, in hME assays, 
the extension primer extends by the addition of a mixture of deoxyribonucleotides 
(dNTPs) and dideoxynucleotides (ddNTPs), so that one allele is extended by a single 
ddNTP, while the other allele is extended by one or more dNTPs followed by a 
ddNTP (Tikka-Kleemola et al 2007)，instead of mass-modified nucleotides in the 
termination mix as in MassARRAY® iPLEX Gold assays. This difference in single 
base primer extension biochemistry renders hME assays less flexible in their assay 
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design compared to Mass ARRAY® iPLEX Gold assays. This will be explained in 
more detail in Chapter 6.4. 
5.2.3 Homogeneous MassEXTEND™ assays (Sequenom) on euploid and T21 
samples 
After optimising the initial PCR reactions, initial PCR was performed on 5 euploid 
and 5 T21 placental DNA samples with Ta = 62 °C. The assays performed were those 
in Table 5.1, except for PV2102d assay which showed poor performance and was 
therefore not further considered, and for ZFY/X assay which was not relevant to the 
differentiation of euploid and T21 samples. 
SAP treatment and hME reactions were performed with the resultant PCR products. 
SAP treatment was done with the protocol as shown in Table 3.4. The preparation of 
the hME reaction mixture and the thermal profile are summarised in Tables 5.2 A 
and B respectively. Primer and product sequences for the hME reactions for the 6 
paralogous sequence assays are shown in Table 5.3. 
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Table 5.2 Homogeneous MassEXTEND™ reactions (Sequenom). 
(A) Composition of homogenous MassEXTEND™ reaction mixture (Sequenom) 
^ Volume for one . x Component , T � Final concentration reaction (队L) 
Deionised water 2.484 -
ddATP (8.96 mM) 0.1 64 gM 
ddTTP (8.96 mM) 0.1 64 i^M 
ddCTP (8.96 mM) 0.1 64 |iM 
dGTP (8.96 mM) 0.1 64 |uM 
Extension primer (10 i^M) 1.08 771.43 nM 
Thermosequenase (32.94 U/|iL) 0.036 0.08 U/^iL 
SAP-treated PCR product 10 : 
Total H : 
(B) Thermal profile of homogenous MassEXTEND™ reactions 
Step Temperature Time 
AmpliTaq Gold® activation 94 °C 2 min 
Denaturation 94 °C 5 s 
75 cycles Annealing 50 °C 5 s 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































After the hME reactions, 24 fxL of water and 6 mg of SpectroCLEAN Resin 
(Sequenom) were added for cleaning up the final extension products. They were then 
subjected to MALDI-TOF MS analysis. The results are shown in Figure 5.2. 
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Figure 5.2 Mass spectrometry results of 6 homogenous MassEXTEND™ assays 
on 5 euploid and 5 T21 placental DNA samples. In the figure, Chr21/Ref chr 
Allelic Freqency Ratio = allele frequency of chr21 peak/allele frequency of reference 




The dosage of chr21 and the reference chromosome should be equal in euploid 
samples, while dosage of chr21 should be 1.5 times that of the reference 
chromosome in T21 samples. Theoretically, the allelic frequency ratio should be 1 
for euploid samples and 1.5 for T21 samples. However, the results from all 6 assays 
showed allelic ratios which deviated a lot from the expected values. Moreover, the 
ranges of allelic ratios from the euploid and T21 group were very close and some 
even overlapped with each other. In other words, the assays failed to differentiate 
between euploid and T21 samples and were therefore not useful. 
5.3 Assay selection by iPLEX® Gold single base primer extension reactions 
(Sequenom) 
Since the euploid and T21 samples could not be differentiated by the hME assays, I 
explored the possibility of the iPLEX® Gold system, another genotyping method 
developed by Sequenom in the beginning of year 2005，for the detection of trisomy 
21. 
The iPLEX® Gold system was tested with a cohort of 5 euploid and 5 T21 placental 
DNA samples. In total 12 paralogous sequence assays were applied. Their primer and 
extension product sequences are summarised in Table 5.4. The iPLEX® Gold single 
base primer extension reaction was performed according to the reaction mixture in 
Table 3.5 A and the thermal profile in Table 3.5 B. The mass spectrometry results 
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Assay optimisation 
Figure 5.3 Mass spectrometry results of 11 iPLEX® Gold assays on 5 euploid 
and 5 T21 placental DNA samples. In the figure, Chr21/Ref chr Allelic Freqency 
Ratio = allele frequency of chr21 peak/allele frequency of reference chromosome 
peak. Data points for euploid and T21 samples are shown in blue and pink 
respectively. Since the allelic ratios for PV2117, PV2107b and PV2102c assays were 
greater than that for the other assays, to avoid compression of the data points for the 
other assays, allelic ratios for PV2117, PV2107b and PV2102c assays are plotted in 
(B) while that for all other assays are plotted in (A). ZFY/X assay targets chrX and 
chrY and was therefore not included in this calculation. 
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Among the 12 iPLEX® Gold assays, PV2106 assay, PV2113 assay, PV2101 assay, 
PV2107a assay and PV2102b assay gave non-overlapping allelic frequency ratios 
between euploid and T21 samples. In other words, these assays could differentiate 
euploid and T21 samples. Among them I selected those specific assays - PV2106 
assay, PV2101 assay, PV2107a assay and PV2102b assay, which were able to 
differentiate between euploid and T21 samples, and continued to develop the 
multiplex paralogous sequence assay with these 4 assays. 
5.4 Optimisation of multiplex PCR with AmpliTaq Gold® DNA polymerase 
The multiplex PV2101 /PV2107a/PV2102b/PV2106 assay was applied on 5 euploid 
and 5 T21 placental DNA samples with 3 different protocols as summarised in Table 
5.5，at Ta = 62 °C. The multiplex PCR products were analysed by gel electrophoresis 
as shown in Figure 5.4. 
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Table 5.5 Composition of multiplex PCR mixture for 
PV2101/PV2107a/PV2102b/PV2106 assay (AmpliTaq Gold® DNA polymerase, 
Applied Biosystems). 
(A) Protocol 1 
^ Volume for one , . Component . _. Final concentration reaction (tiL) 
Deionised water 14.2 -
1 OX PCR buffer II 2.5 lx 
MgCl2 (25 mM) 1 1 mM 
dATP (10 mM) 0.75 0.3 mM 
dTTP (10 mM) 0.75 0.3 mM 
dCTP(lOmM) 0.75 0.3 mM 
dGTP (10 mM) 0.75 0.3 mM 
® 
AmpliTaq Gold DNA 0.3 0.06 U/^tL 
Polymerase (5 U/(iL) 
PV2101 Forward Primer (10 jiM) 0.25 0.1 |iM 
PV2107a Forward Primer (10 |iM) 0.25 0.1 \iM 
PV2102b Forward Primer (10 jiM) 0.25 0.1 \ M 
PV2106 Forward Primer (10 i^M) 0.25 0.1 i^M 
PV2101 Reverse Primer (10 _ 0.25 0.1 \iM 
PV2107a Reverse Primer (10 _ 0.25 0.1 |iM 
PV2102b Reverse Primer (10 |iM) 0.25 0.1 (iM 
PV2106 Reverse Primer (10 jiM) 0.25 0.1 \ M 
DNA sample 2 -
Total 25 � 
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(B) Protocol 2 
Volume for one . x Component ‘. , T � Final concentration reaction (nL) 
Deionised water 11.075 -
10X PCR buffer E 3.125 1.25X 
MgCl2 (25 mM) 1.5 1.5 mM 
dATP(lOmM) 1.25 0.5 mM 
dTTP (10 mM) 1.25 0.5 mM 
dCTP(lOmM) 1.25 0.5 mM 
dGTP (10 mM) 1.25 0.5 mM 
® 
AmpliTaq Gold DNA 0.3 0.06 U/|iL 
Polymerase (5 U/|iL) 
PV2101 Forward Primer (10 \M) 0.25 0.1 [M 
PV2107a Forward Primer (10 |iM) 0.25 0.1 i^M 
PV2102b Forward Primer (10 |IM) 0.25 0.1 jiM 
PV2106 Forward Primer (10 i^M) 0.25 0.1 ^M 
PV2101 Reverse Primer (10 _ 0.25 0.1 [iM 
PV2107a Reverse Primer (10 |iM) 0.25 0.1 
PV2102b Reverse Primer (10 _ 0.25 0.1 \xM 
PV2106 Reverse Primer (10 |iM) 0.25 0.1 |iM 




(C) Protocol 3 
Volume for one . 丄丄 • Component , T � Final concentration reaction (^L) 
Deionised water 9.775 -
1 Ox PCR buffer II 3.125 1.25X 
MgCl2 (25 mM) 2.8 2.8 mM 
dATP (10 mM) 1.25 0.5 mM 
dTTP (10 mM) 1.25 0.5 mM 
dCTP (10 mM) 1.25 0.5 mM 
dGTP (10 mM) 1.25 0.5 mM 
AmpliTaq Gold® DNA 0.3 0.06 U/^ iL 
Polymerase (5 U/|iL) 
PV2101 Forward Primer (10 \M) 0.25 0.1 \xM 
PV2107a Forward Primer (10 jjM) 0.25 0.1 jiM 
PV2102b Forward Primer (10 |iM) 0.25 0.1 \M 
PV2106 Forward Primer (10 \xM) 0.25 0.1 |iM 
PV2101 Reverse Primer (10 [iM) 0.25 0.1 |iM 
PV2107a Reverse Primer (10 |iM) 0.25 0.1 
PV2102b Reverse Primer (10 |aM) 0.25 0.1 [M 
PV2106 Reverse Primer (10 jiM) 0.25 0.1 \xM 
DNA sample 2 ： 
Total 25 ： 
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M l 2 3 4 5 6 7 8 9 10 N 
p r o t o c o l 1 — — 
100 bp ^ P 
H H H H H H H H H 
FlBil _ 
100 bp • 
Protocol 3 
Figure 5.4 PCR amplification products from multiplex PCR with 3 different 
protocols for PV2101/PV2107a/PV2102b/PV2106 assay. In the figure, M denotes 
the 100 bp DNA Step Ladder (Promega，U.S.A.). On top of each well，1-5 and 6-10 
denote the 5 euploid and 5 T21 DNA samples as templates respectively. N denotes 
the no template controls. 
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The 3 protocols differed in the magnesium ion concentration, with protocol 1 having 
the lowest magnesium ion concentration and protocol 3 having the highest 
magnesium ion concentration. Magnesium chloride is an enzyme co-factor necessary 
for polymerases. It functions by binding of the magnesium ion to the enzyme, 
inducing a conformational shift and putting the subunits to the correct configuration 
for functioning (Devor et al.). Inadequate magnesium ion reduces the amount of 
product. However, excessive magnesium ion prevents complete denaturation of DNA 
by stabilising the DNA double strand, therefore would reduce the product yield. It 
also stabilises spurious annealing of primer to incorrect template sites, thus decreases 
specificity (Markoulatos et al 2002). 
As shown in Figure 5.4，the gel photo from protocol 3 showed the brightest DNA 
product bands for all the samples, indicating the greatest amount of PCR products 
produced, while having the least primer dimer formation when compared with 
protocol 1 and 2. With protocol 3，the primers were most efficiently converted into 
products. The amplification was specific, as no product bands could be observed in 
the negative control. Therefore, protocol 3 with the highest magnesium ion 
concentration was selected as the optimal one for the multiplex PCR reaction. 
5.5 Optimisation of multiplex iPLEX® Gold single base primer extension 
reaction 
After optimising the multiplex PCR reaction, I proceeded to optimise the multiplex 
iPLEX® Gold reaction with the PV2101 /PV2107a/PV2102b/PV2106 assay. However, 
for PV2106 assay, the iPLEX® Gold extension primer extends by the addition of 
mass-modified nucleotides G and A on chr21 and chr6 respectively. The mass 
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difference between the two iPLEX® Gold extension products terminating with A and 
G would be 16 Da, which is the smallest among all combinations of terminators, 
according to the application notes from Sequenom. Therefore, the iPLEX® Gold 
extension primer of this assay was re-designed. Instead of the forward direction, the 
new iPLEX® Gold extension primer was designed in the reverse direction, so that it 
extends by the addition of the nucleotides C and T on chr21 and chr6 respectively. 
The resulting extension products would then have a mass difference of 79.9 Da, 
which would be more easily resolved. The newly designed assay was named 
PV2106_R assay, where R indicates that the extension primer was designed in the 
reverse direction. The new primer and product sequences are listed in Table 5.6. 
Together with the other 3 assays, the multiplex iPLEX® Gold assay was tested on 2 
euploid and 2 T21 placental DNA samples. The initial PCR was performed according 
to protocol 3 in Chapter 5.4. The preparation of the iPLEX® Gold reaction mixture 
is summarised in Table 5.7. To avoid competition of resources in the primer 
extension reaction and low peak intensities, the total concentration of the iPLEX® 
Gold extension primers was doubled when compared to monoplex reactions. The 
amount of termination mix added to the reaction mixture was also increased. Due to 
the inverse relationship between peak intensity and analyte mass, the Sequenom 
application notes suggest that the concentration of high mass primers should be 
doubled with respect to low mass primers. Therefore, in the multiplex assay, the 
highest mass extension primer, PV2106—R extension primer, was diluted to 30 jiM 
instead of 10 ^iM. The thermal profile was the same as in Table 3.5 B. The resulting 










































































































































































































































































































Table 5.7 Composition of multiplex iPLEX® Gold reaction mixture (Sequenom) 
for PV2101/PV2107a/PV2102b/PV2106_R assay. 
_ Volume for one . x Component , T � Final concentration reaction (iiL) 
Deionised water 0.4785 -
iPLEX Buffer Plus (lOx) 0.3 0.22X 
ddATP (40 mM) 0.125 0.37 mM 
ddTTP (40 mM) 0.125 0.37 mM 
ddCTP (40 mM) 0.125 0.37 mM 
ddGTP (40 mM) 0.125 0.37 mM 
PV2101 Extension primer (10 |iM) 0.54 0.4 i^M 
PV2107a Extension primer (10 (iM) 0.54 0.4 |iiM 
PV2102b Extension primer (10 |iM) 0.54 0.4 |iiM 
PV2106_R Extension primer (30 |iM) 0.54 1.2 |iM 
iPLEX Enzyme (220x) 0.0615 lx 
SAP-treated PCR product 10 ： 
















































































































































































































































































































Figure 5.5 Mass spectra from multiplex iPLEX® Gold 
PV2101/PV2107a/PV2102b/PV2106_R assay. (A) and (B) are spectra with euploid 
and T21 placental DNA samples as templates respectively. In each spectrum, the 
x-axis depicts the molecular mass of the ions and the 少-axis depicts the intensity in 
arbitrary units. UEP denotes the unextended primer. Only one spectrum from each 
sample group is shown. 
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In Figure 5.5, for both spectra, the 2 product peaks of PV2106_R assay were readily 
resolvable, due to a mass difference of 79.9 Da between the 2 products. Except 
PV2101 assay, all assays showed similar intensity for the chr21 and reference 
chromosome peak for the euploid sample, while the 2 peaks were skewed, with a 
higher intensity for the chr21 peak for the T21 sample. For PV2101 assay, the 
intensity of chrl peak for both euploid and T21 samples was very low. Therefore, in 
an attempt to increase the peak intensity, the concentration of termination mix added 
to the reaction mixture was further increased to 0.48 mM per reaction for each 
ddNTP. Moreover, since the mass of the unextended primer of PV2106—R assay was 
between that of the 2 extension products of PV2101 assay, another new extension 
primer was designed by adding 2 more nucleotides to the 5' end of the PV2106—R 
extension primer so that the mass of the new primer would be increased and the 
peaks would be more widely separated. Studies have shown that more than half of 
the coupling failures occur within the first 6 bases from the 3’ end of the primer, and 
almost none occur near the 5' end (Hecker and Rill 1998; Temsamani et al. 1995). 
Therefore adding bases to the 5' end would not affect the coupling of the primer. The 
newly designed primer was named PV2106_L primer, where L denotes the longer 
extension product length. Its primer and product sequences are listed in Table 5.8. 
With the new extension primer and increased amount of ddNTPs added, the 
multiplex iPLEX® Gold assay was performed on a euploid placental DNA sample. 
The preparation of the iPLEX® Gold reaction mixture is summarised in Table 5.9. 
The thermal profile was the same as in Table 3.5 B. The resulting mass spectrum is 













































































































































































































































































































Table 5.9 Composition of multiplex iPLEX® Gold reaction mixture (Sequenom) 
for PV2101/PV2107a/PV2102b/PV2106_L assay. 
^ Volume for one . . Component 丄 . , T � Final concentration reaction (nL) 
Deionised water 0.3285 -
iPLEX Buffer Plus (lOx) 0.3 0.22X 
ddATP (40 mM) 0.1625 0.48 mM 
ddTTP (40 mM) 0.1625 0.48 mM 
ddCTP (40 mM) 0.1625 0.48 mM 
ddGTP (40 mM) 0.1625 0.48 mM 
PV2101 Extension primer (10 jxM) 0.54 0.4 
PV2107a Extension primer (10 (iM) 0.54 0.4 |xM 
PV2102b Extension primer (10 ^M) 0.54 0.4 |iM 
PV2106_L Extension primer (30 [M) 0.54 1.2 mM 
iPLEX Enzyme (220x) 0.0615 IX 
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Figure 5.6 Mass spectrum from multiplex iPLEX® Gold 
PV2101/PV2107a/PV2102b/PV2106_L assay. A euploid placental DNA sample 
was used as the template. Increased amount of ddNTPs was added in the reaction. In 
the spectrum, the x-axis depicts the molecular mass of the ions and the 少-axis depicts 
the intensity in arbitrary units. UEP denotes the unextended primer. 
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In Figure 5.6, for all assays the intensity of chr21 peak and the reference 
chromosome peak were very similar. For PV2101 assay, the chrl peak intensity 
became higher. Also, since the extension primer of PV2106_L assay had a greater 
mass, the peaks of this assay were completely separated from that of PV2101 assay. 
Thus, the finalised conditions for the iPLEX® Gold multiplex assay with PV2101, 
PV2107a, PV2102b and PV2106—L are shown in Table 5.9 and Table 3.5 B. 
5.6 Single molecule detection test for the multiplex paralogous sequence assays 
The single molecule detection test was performed to ensure that the detection limit of 
a digital PCR experiment for each amplicon of each assay is down to single molecule. 
To do this, the DNA sample was diluted to obtain aliquots of different template 
concentrations at 2-fold dilutions. In total 5 dilutions were prepared, with each 
analysed on a 384-well plate. The aliquot with the lowest dilution was aimed to give 
approximately 1% of wells positive and this concentration was defined as the 
calibration reference. Let the average template concentration per well of the 
calibration reference be x copies/well. For the aliquots with average template 
concentrations of 2x, 4x, 8x and 16x, the numbers of positive wells for each 
amplicon were counted. The log2(percentage of positive wells) was plotted against 
the log2(fold increase in average template concentration) for these aliquots. 
If the detection limit is single molecule, there should be an approximately 2-fold 
increase in the amount of positive wells for each 2-fold increase in template 
concentration at this very diluted template concentration. Therefore, in the plot, a 
straight line with a slope of -0.97 should be observed. However, when the detection 
limit is 2 molecules, there would be a 3.6-fold increase in the number of positive 
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wells when the template concentration is doubled. A further 2-fold increase in 
template concentration would give another 3.3-fold increase in the number of 
positive wells. The slope of the resulting plot would be -1.5, which is much greater 
than 0.97. Figure 5.7 shows the detection limit plots when the detection limit = 1, 2, 
3 and 4. Figure 5.8 shows the detection limit plots for each amplicon for each 
paralogous assay. 
Detection limit = 4 , 
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Figure 5.7 Detection limit plots when the detection limit = 1，2，3 and 4. 
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Figure 5.8 Detection limit plots for the digital paralogous sequence assays. 
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For each amplicon, the detection limit plot gave a slope close to 0.97, supporting that 
the sensitivities of these assays were down to the single molecule level. The only 
exception was the chr7 amplicon for PV2107a assay, which gave a slope in between 
that when detection limit = 1 and 2. The reason for that was the extremely low 
positive well count at the lowest average template concentration for this amplicon. At 
this low concentration, there may be a chance that fewer template molecules than 
expected were distributed to the plate for analysis, leading to a lower positive well 
count. Since the data point at the lowest template concentration greatly affected the 
plot, the slope was much increased. The plot showed that the assay performance of 
PV2107a may be worse than the other assays, but at higher template concentrations 
the approximately 2-fold increase in positive wells per 2-fold increase in template 
concentration showed that the assay should have reasonable performance. 
Concluding remark 
In this chapter, the whole process of assay optimisation is introduced. PV2106 assay, 
PV2101 assay, PV2107a assay and PV2102b assay were selected to develop the 
multiplex paralogous sequence assay. The reaction conditions of the multiplex PCR 
and iPLEX® Gold single base primer extension reaction were also optimised. The 
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CHAPTER 6: DISEASE CLASSIFICATION OF EUPLOID AND 
TRISOMY 21 SAMPLES WITH MULTIPLEX PARALOGOUS 
SEQUENCE ASSAY 
6.1 Introduction 
In Section III，I optimised a multiplex assay that is analytically specific for the 
paralogous sequences concerned using the iPLEX® Gold technology on the 
Sequenom platform. The next step towards developing the assay into a tool for the 
non-invasive prenatal diagnosis of fetal trisomy 21 is to apply the assay on clinical 
samples. The success of the multiplex assay would rely on whether it allows correct 
disease classification of the samples as euploid or T21. Fetal DNA circulates in 
maternal plasma within a high background of maternal DNA, contributing some 10% 
of all DNA in maternal plasma (Lo et al. 1998b; Lun et al. 2008a). Low fetal DNA 
concentration in maternal plasma has led to false-negative results and wrong 
diagnoses (Chan et al 2006). Quantitative analysis of circulating fetal DNA is also 
less precise at low concentrations (Lo et al 2007a). Therefore, before applying the 
multiplex assay on maternal plasma samples, which is the ultimate goal in 
non-invasive prenatal diagnosis, in this chapter, I first tested the assay on euploid and 
T21 placental DNA samples, which are 100% fetal in their DNA composition. The 
assay was then tested on artificial DNA mixtures between euploid and T21 placental 
DNA and euploid maternal blood cell DNA, with varying fractional fetal DNA 
concentrations. A sex-mismatched bone marrow transplant model has previously 
demonstrated that the majority (median �60% ) of circulating DNA molecules in 
plasma are haematopoietic in origin (Lui et al. 2002). For the origin of cell-free fetal 
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DNA in maternal plasma, the most accepted hypothesis is the direct release from the 
placenta due to cellular apoptosis (Tjoa et al. 2006). Therefore, the artificial DNA 
mixtures are actually analogous to the maternal plasma samples in terms of the DNA 
composition. The successful and correct classification of these placental samples and 
artificial DNA mixtures would demonstrate that the multiplex digital RCD approach 
is applicable to nonpure fetal DNA samples. The analysis would also give us an idea 
on how much DNA template molecules would be needed to achieve correct disease 
classification on different fractional fetal DNA concentrations. These fundamental 
data would facilitate the development of the assays and made a significant step 
towards the clinical diagnostic application using maternal plasma samples. 
6.2 Materials and methods 
6.2.1 Sample collection 
All the placental tissue and maternal peripheral blood samples were collected from 
the Department of Obstetrics and Gynaecology, Prince of Wales Hospital, Hong 
Kong, with institutional ethical approval. The study was approved by the Institutional 
Review Board. Subjects with singleton pregnancies were recruited with informed 
consent between October 2007 and May 2008. 
Post-delivery maternal peripheral blood samples were collected into 
ethylenediaminetetraacetic acid (EDTA)-containing tubes 24 hours after the 
performance of obstetrical procedures. In total 4 cases of maternal blood samples 
were collected for the preparation of post-delivery maternal blood cell DNA. For 
each case, 12 mL of blood was collected. All the samples were processed using the 
protocol described in Chapter 3.2. 
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Euploid placental tissue samples were collected after elective caesarean section at 
term (gestational age range: 38-39 weeks), while T21 placental tissue samples were 
collected after termination of pregnancy in the first trimester (gestational age: 13 
weeks). Fetal karyotypes were confirmed by full karyotyping. In total 4 cases of 
euploid (3 male and 1 female fetuses) and 2 cases of T21 placental tissue samples 
were collected for the preparation of placental DNA. 
6.2.2 Experimental design 
After extraction of DNA from the placental tissue samples and the maternal blood 
samples, the DNA extracted was quantified by spectrophotometry (NanoDrop 
Technologies, Wilmington, DE). In the experiment, pure fetal DNA, artificial DNA 
mixtures containing 50% and 25% of euploid or T21 placental DNA in a background 
of euploid maternal blood cell DNA were analysed. Placental DNA from 2 T21 and 2 
euploid cases was each mixed with an equal amount of euploid maternal blood cell 
DNA, producing 4 DNA mixtures of 50%. In the same way, placental DNA from 2 
T21 and 2 euploid cases was each mixed with a 3-fold excess of euploid maternal 
blood cell DNA, producing 4 DNA mixtures of 25%. For pure fetal DNA, all the 4 
cases of euploid and 2 cases of T21 placental DNA were analysed. All DNA samples 
were diluted to an extremely low concentration, at around 0.625 G E / j i L , to achieve a 
DNA concentration of one template molecule per reaction well on average. Relative 
chromosome dosage analysis was then carried out using the digital multiplex assay 
as described in Chapter 3.6.2. For each case, the numbers of wells positive for chr21 
and the reference chromosome were scored independently for individual assay, 
according to the call output by the TyperAnalyzerFS programme. The data from each 
assay were then pooled together by adding the Poisson-corrected numbers of 
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molecules of chr21 and the reference chromosome from the 4 assays. The Pr value, 
which is the proportion of chr21 counts among all informative counts, was calculated 
for each individual assay as if each assay was performed individually, as well as the 
pooled results. The digital PCR data were then interpreted by SPRT analysis as 
described in Chapter 3.6.3 and 3.6.4. The samples would be further analysed until 
disease classification was achieved. 
6.3 Results 
The digital PCR data for all the cases analysed at each fractional fetal DNA 
concentration are shown in Appendix II. Data for fetal DNA concentrations of 100%, 
50% and 25% are shown in Tables i, ii and iii, respectively. In each table, the 
Poisson-corrected numbers of molecules of chr21 and the reference chromosomes for 
the multiplex assay and also their Pr values were calculated. Each Pr value was 
interpreted by SPRT for disease classification. Subtotal values show the sum of all 
previous data, until finally the total values for the case allowed it to be correctly 
classified. 
The SPRT classification results of all the cases analysed are plotted on the SPRT 
curves as shown in Figure 6.1. 
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Figure 6.1 SPRT interpretations of digital RCD analyses. (A) Pure placental DNA 
samples. (B) DNA mixtures containing 50% placental DNA/maternal blood cell 
DNA. (C) DNA mixtures containing 25% placental DNA/maternal blood cell DNA. 
The smaller data points represent the monoplex results while the larger data points 
represent the multiplex results. Euploid cases are shown in blue while T21 cases are 
shown in pink. 
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All the pure placental DNA samples and the DNA mixtures containing 50% and 25% 
fetal DNA were correctly classified by the multiplex data. For pure placental DNA, 
all samples were classified by one 384-well plate, except one which needed 4 plates 
for disease classification (Appendix II, Table i). For the 50% DNA mixture, the 
number of 384-well plates required for disease classification ranged from one to five 
(Appendix II，Table ii). For the 25% DNA mixture, the number of 384-well plates 
needed ranged from one to five (Appendix II，Table iii). Most of the monoplex data 
points were in the unclassifiable region, while the multiplex data points reached the 
point of being classifiable. This demonstrated the effect of multiplexing in increasing 
the total number of informative counts with the same maternal plasma input volume 
to allow classification of the samples. 
6.4 Discussion 
In my project, I developed a multiplex paralogous sequence assay targeting chr21 
and four other reference chromosomes and demonstrated its feasibility in the 
detection of fetal trisomy 21. Indeed, Lo et al. previously demonstrated the use of 
monoplex digital PCR to successfully diagnose fetal trisomy 21 using digital 
real-time PCR (Lo et al. 2007a). However, computer simulation showed that to 
correctly classify 97% of both euploid and aneuploid cases at a fetal DNA 
concentration of 25%, a total number of 7,680 PCR analyses would be needed 
(Appendix I) (Lo et al 2007a). The number of DNA molecules per unit volume of 
maternal plasma is limited (Lo et al 1998b). Previous findings discovered that in 
early pregnancy, the median maternal plasma concentration of an autosomal locus, 
the (3-globin gene, which was originated from both the fetus and mother, was 986 
copies per millilitre (Lo et al 1998b). To obtain 7,680 DNA molecules for digital 
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PCR analysis, DNA extracted from some 8 mL of maternal plasma, meaning 15 mL 
of maternal blood, would be needed. 
To make the digital RCD approach more practicable, the multiplex assay was 
developed. Since DNA molecules in maternal plasma are fragmented (Chan et al. 
2004)，by simultaneously amplifying 4 sets of paralogous sequences on chr21 and 
chromosomes 1，2，6 and 7 as reference chromosomes, multiple counting of chr21 
could be performed. This would virtually increase the number of template molecules 
per unit volume of plasma, and thus less plasma would be required to achieve the 
same accuracy in the diagnosis. For instance, for the 4-plex assay I developed, the 
volume of maternal plasma needed would reduce by 4-fold, implying that only 2 mL 
of plasma would be needed to achieve 97% classification accuracy, instead of the 
original 8 mL when monoplex assay was performed. Moreover, digital RCD is not a 
polymorphism dependent approach, unlike RNA-SNP (Lo et al 2007b) and 
epigenetic allelic ratio analysis (Tong et al 2006)，which can only be applied on 
heterozygous fetuses. Since the performance of digital RCD is better for cases with a 
higher fractional fetal DNA concentration, the approach can be readily applied to 
samples containing virtually pure fetal DNA, such as amniotic fluid and chorionic 
villus samples, for the disease classification. 
Digital PCR offers a much higher precision in DNA quantification than traditional 
methods such as real-time PCR, as each template molecule is counted individually. 
This is of particular importance when the degree of overrepresentation of chr21 in 
T21 pregnancies is so small. Unlike real-time PCR, digital PCR is independent of 
dose-response relationship between reporter dyes and DNA concentration, making it 
insensitive to fluctuations in amplification efficiency (Fan and Quake 2007). 
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In our experiments, the multiplex assays were performed with the MassARRAY® 
iPLEX Gold technology on the Sequenom platform, instead of the real-time PCR 
platform. This is attributed to a number of reasons. Firstly, since real-time PCR 
depends on the use of fluorescence reporters to distinguish the products from the 
various loci, one would quickly run out of reporters since the number of them is 
limiting (Chiu et al 2008). Secondly, as my work is to perform multiplex analysis of 
multiple genetic loci, the Sequenom platform, which allows assays at multiplexing 
level of 36-plex with greater than 99.7% accuracy, would be a more appropriate one 
for future development. However, the optimisation of highly multiplexed digital PCR 
might be challenging. Therefore, the MassARRAY® iPLEX Gold system, which 
allows more flexible assay design, was selected instead of the homogeneous 
MassEXTEND™ system. In the reaction mixture, all four mass-modified 
nucleotides—A, T, C，and G—are present. The use of this single termination mix 
allows higher multiplexing level to be achieved, which would be difficult for the 
homogeneous MassEXTEND™ system, in which the primer extends by a 
combination ofdNTPS and ddNTPs. 
The iPLEX Gold SNP genotyping has been widely used in many research areas. It 
allows the sensitive and quantitative detection of low abundance mutations in 
mixtures of cancer and healthy tissue (Thomas et al 2007; Vivante et al. 2007). 
Other applications include validation of whole genome association studies (Abel et al. 
2006; Rioux et al. 2007; Sladek et al 2007)，allelotyping of pooled samples (Costas 
et al 2005; Mueller et al 2005)，disease association studies (Ali et al 2007; 
Cummings et al 2007; Gumieniak et al 2007) and so on. 
SPRT analysis was applied for disease classification of the various samples. It is a 
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statistical tool to determine whether the overrepresentation of chr21 reaches 
statistical significance. SPRT has been used to interpret digital PCR data for loss of 
heterozygosity (LOH) in tumour samples by Zhou et al. (Zhou et al 2001; Zhou et al 
2002). In their setting, two hypotheses were set. Hypothesis 1 was that a sample had 
no LOH, that is, the alleles had the same proportion in the tumour cells as they did in 
normal cells. This would correspond to P = 50%, where P is the allelic proportion in 
the overall sample. Hypothesis 2 was that the same one of the two alleles was absent 
in every tumour cell. They made a conservative assumption that at least 50% of the 
DNA from the samples originated from neoplastic cells rather than normal cells. The 
hypothesis of LOH would then correspond to P >66.7%. An SPRT was therefore 
constructed to choose between the hypotheses P = 50% and P = 66.7%. Fixed curves 
were used for the classification (Zhou et al 2001). However, since their assumption 
might not be true, misclassification might result. Therefore, alternative statistical 
methods based on the false discovery rate (El Karoui et al. 2006) could be further 
evaluated in the future. 
In my studies, the SPRT analysis was further refined by constructing SPRT curves 
specific for the fractional fetal DNA concentration of the samples. Compared to the 
fixed curves approach, this would greatly increase the proportion of samples 
correctly classified (Lo et al. 2007a). Since the fractional fetal DNA concentration 
has to be known for the selection of the appropriate set of SPRT curves for disease 
classification, an accurate method for the determination of fetal DNA concentration 
would be important. This is why the ZFY/X assay was included in the optimisation 
process. The ZFY/X assay targets the homologous zinc finger protein Y-linked and 
zinc finger protein X-linked on chromosomes Y and X respectively, so by counting 
the number of molecules of chromosomes Y and X，the fetal DNA concentration can 
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be calculated. 
This proof-of-principle study demonstrated that multiplex digital RCD is a feasible 
and robust approach for the prenatal diagnosis of fetal trisomy 21. The samples could 
be correctly classified even when the fetal DNA was of minor proportion. For the 
pure euploid and T21 placental DNA samples (Appendix II，Table i), for all 6 cases, 
some monoplex assays did not reach disease classification. However, the multiplex 
results allowed all of them to be correctly classified. This was even more evident for 
the 50% and 25% euploid and T21 artificial DNA mixtures (Appendix II，Tables ii, 
iii), where almost all the monoplex assays did not reach disease classification, but 
multiplex results did. This illustrated that multiplexing could greatly increase the 
calling rate by increasing the number of informative counts, compared to monoplex 
assays. 
Fetal DNA constitutes only 3.4% (range 0.39%-11.9%) and 6.2% (range 
2.33%-11.4%) of the total plasma DNA in early and late pregnancy, respectively (Lo 
et al. 1998b). Though later research with the microfluidics digital PCR platform 
discovered that the median fractional concentration of fetal DNA in maternal plasma 
was at least 2 times higher for all 3 trimesters of pregnancy than previously reported 
(Lun et al 2008a), fetal DNA was still present as a minor population. Since at lower 
fractional fetal DNA concentration, the number of template molecules needed to 
achieve disease classification would increase, to make the digital RCD approach 
more clinically applicable, methods to attain a higher fetal DNA concentration would 
be needed. To increase the fetal DNA concentration, one can either selectively enrich 
fetal DNA (Li et al 2004), or suppress the maternal background DNA (Dhallan et al. 
2004; Dhallan et al 2007). Several groups have worked on different methods to 
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increase the fractional fetal DNA concentration. Dhallan et al. reported that when 
treated with formaldehyde, 85% (51 of 60) of their plasma samples had fractional 
fetal DNA concentrations >25% (Dhallan et al. 2007). Benachi et al. also reported a 
mean fetal DNA concentration of 36.8% in their formaldehyde-treated plasma 
samples (Benachi et al. 2005), though the effect of formaldehyde has not been 
universally observed (Chinnapapagari et al. 2005; Chung et al. 2005). Apart from 
physical methods, molecular strategies were also developed for the selective 
enrichment of fetal DNA. One way is to target fetal DNA molecules with a particular 
DNA methylation pattern (Chan et al. 2006; Chim et al. 2005; Chiu et al 2007). The 
aim is to search for CpG sites that exhibit different DNA methylation patterns in the 
placenta and maternal blood cells. Recently, placenta-specific DNA methylation 
markers on chr21 have been identified (Chim et al. 2008; Old et al. 2007). These 
markers can be used for the development of maternal plasma-based epigenetic test 
for the non-invasive prenatal diagnosis of fetal trisomy 21, either by analysis of 
epigenetic allelic ratios (Tong et al. 2006) or by direct comparison with a 
placenta-specific DNA methylation marker on a reference chromosome (Chim et al 
2008). Multiplex digital RCD assays targeting loci with different methylation 
patterns between the mother and the fetus may also be developed. 
Another recently developed strategy for fetal DNA enrichment is by digital nucleic 
acid size selection (NASS) (Lun et al 2008b). DNA molecules in maternal plasma 
are fragmented, with the fetal ones shorter than the background maternal ones (Chan 
et al 2004). Based on this phenomenon, Li et al used gel electrophoresis to select 
for short DNA molecules in maternal plasma for fetal DNA enrichment and reported 
improved sensitivities in detecting fetal p-thalassaemia point mutations (Li et al. 
2005). However, the drawback of this method is that gel electrophoresis is prone to 
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DNA contamination. Digital NASS is based on performing duplex digital PCR on 
single DNA molecules. The duplex assay targets one short amplicon and one long 
amplicon respectively. Digital PCR is performed using two forward primers and one 
reverse primer, or vice versa, that are oriented to produce a short amplicon 
overlapping with a long amplicon. When a single DNA molecule at least as long as 
the long amplicon is present in a reaction well, both the long and short PCR products 
are produced. For a single DNA molecule shorter than the span of the long amplicon, 
only the short PCR product is generated. The presence of the long and/or short 
amplicons can be detected by primer extension reaction on the mass spectrometric 
platform. As fetal DNA is shorter than the maternal DNA, fetal DNA would be more 
highly represented among the short DNA pool. Therefore a higher effective fetal 
DNA concentration would be achieved by counting of the short DNA molecules only 
(Lun et al 2008b). The advantage of NASS is that it allows locus-specific 
enrichment of fetal DNA. No extra sampling of maternal plasma or additional 
experimental time is needed. Furthermore, it is complementary to other methods that 
physically enrich fetal DNA. Further fetal DNA enrichment can then be achieved 
(Lun et al 2008b). All of the described fetal DNA enrichment approaches can be 
used in combination with multiplex digital RCD assays to ultimately achieve direct 
detection of fetal aneuploidy from maternal plasma. 
Finally, though in my project I demonstrated the use of paralogous sequences as the 
multiplex assay targets, in principle, non-paralogous loci can also be used. 
Paralogous sequences were targeted in my project because they could be 
co-amplified by a common pair of primer, which would allow easier optimisation, 
more comparable PCR systems and similar amplification efficiencies. Given the 
robustness of multiplex single-molecule analysis demonstrated previously in 
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single-molecule haplotyping (Ding and Cantor 2003)，using non-paralogous targets 
should be a feasible approach. Recently, Chiu et al and Fan et al demonstrated the 
use of a locus-independent approach for the non-invasive prenatal diagnosis of fetal 
chromosomal aneuploidies (Chiu et al 2008; Fan et al 2008) by massively parallel 
genomic sequencing (MPGS) (Margulies et al 2005; Rodriguez et al 2008; Schuster 
2008). In their studies, the Illumina Solexa sequencing technique (Dear 2003) was 
employed as the MPGS platform. The plasma DNA fragments were clonally 
expanded, and one end of the copies was sequenced. The sequences were aligned by 
software to the human reference genome for the determination of the chromosomal 
origin of the sequenced plasma DNA fragments. Then, the number of sequence reads 
originating from each chromosome was counted, and the relative genomic 
representation of plasma DNA molecules can be quantified. In the studies, the 
differences in amounts of chr21 DNA sequences in maternal plasma for T21 
pregnancies compared with euploid pregnancies could be clearly detected (Chiu et al 
2008; Fan et al. 2008). Under this approach, as no specific gene locus was targeted, 
all DNA fragments in a plasma sample could be sequenced. This quantitative 
genomic sequencing approach allowed an increased number of target molecules from 
the aneuploid chromosome to be analysed for its quantification. As very large 
number of molecules was analysed with the MPGS platform, the imprecision of 
measurement could be minimised. However, a limitation of this method is the 
relatively high costs, with sequencing reagents alone costing US$700 for each 
sample (Chiu et al. 2008). Such technology would have to become more affordable 
before it can be applied in common clinical settings. In this regard, the multiplex 
RCD approach that I have developed may offer a cheaper alternative. 
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CHAPTER 7: CONCLUSION AND FUTURE PERSPECTIVES 
7.1 Conclusion 
Theoretically, even with a small fractional fetal DNA concentration (Lo et al. 1998b; 
Lun et al 2008a), a T21 fetus would contribute an additional dose of chr21 
sequences per genome equivalent of fetal DNA released into maternal plasma. There 
will be a small degree of overrepresentation of chr21 compared to other non-trisomic 
chromosomes. This small degree of quantitative difference can be detected by digital 
PCR (Vogelstein and Kinzler 1999)，which counts every DNA template molecule and 
thus offers a high quantitative precision. 
Based on this theory, the digital RCD approach was developed. This project is a 
further development of the digital RCD approach and summarises the development 
of a multiplex digital paralogous sequence assay and its successful application in 
classifying euploid and T21 samples. Unlike some previously mentioned methods, 
digital RCD is a universal approach for the prenatal diagnosis of trisomy 21. It is 
sex- and polymorphism-independent, with high precision in DNA quantification. 
Samples are classified by SPRT statistics which is refined to be adaptable to varying 
fetal DNA concentrations, and allows a greater proportion of samples to be correctly 
classified, with a smaller amount of testing compared to other statistical methods. 
Development of the multiplex assay allows more DNA molecules to be counted per 
unit volume of maternal plasma, so that less maternal blood is needed for the test. As 
fetal trisomy 21 could be detected with lower volumes of maternal blood by the 
digital multiplex assay, this actually brings non-invasive prenatal diagnosis of fetal 
trisomy 21 closer to clinical applicability. 
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7.2 Future perspectives 
For future development, as mentioned in Chapter 6.4, non-paralogous sequences can 
also be targeted for the quantification of the aneuploid chromosome. This would 
greatly increase the number of target molecules from the aneuploid chromosome 
analysed, therefore further reduce the amount of maternal blood needed for the 
diagnosis. This approach should be further developed with the availability of the 
MPGS platform (Margulies et al. 2005; Rodriguez et al. 2008; Schuster 2008). 
Apart from fetal trisomy 21, we can identify more DNA markers on other autosomes 
and sex chromosomes in the human genome for the prenatal diagnosis of fetal 
trisomy 18，trisomy 13 and sex chromosomal aneuploidies. The principle of digital 
RCD can also be applied to the detection of other diseases associated with allelic 
imbalance. This includes monogenic diseases such as cystic fibrosis and 
p-thalassemia. Recently Lun et al. reported the use of digital relative mutation 
dosage (RMD) on pregnant women heterozygous for a disease-causing gene for the 
determination of the fetal genotype (Lun et al 2008b). It works by determining 
whether dosages of the mutant and wild-type allele of the disease-causing gene are 
balanced or not in the maternal plasma. If both the mother and the fetus are 
heterozygous, allelic balance should be observed. In the case of allelic imbalance, 
underrepresentation of the mutant allele compared to the wild-type allele suggests a 
homozygous normal fetus, and overrepresentation of the mutant allele suggests a 
homozygous mutant fetus (Lun et al 2008b). We can see that digital RMD is very 
similar to digital RCD in principle. In both approaches, both the maternal and fetal 
contributions are counted when calculating the mutant to wild-type allelic ratio (Lun 
et al. 2008b). This example illustrated the general application of the principle of 
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digital RCD on the diagnosis of diseases associated with allelic imbalance. 
Performing digital RCD analysis is rather labour-intensive, involving manual 
distribution of the sample DNA into the reaction wells of 384-well plates and many 
post-PCR steps. To make it technically applicable in clinical settings, more 
automated strategies would need to be developed, such as microfluidics (Lun et al 
2008a; Warren et al 2006), variants of emulsion PCR (Diehl et al 2005; Dressman et 
al 2003), and various approaches for massively parallel sequence analysis (Chiu et al 
2008; Margulies et al. 2005) as mentioned. Alternative strategies such as melting 
curve analysis (Montgomery et al. 2007; Nakagawa et al. 2008; Polin et al. 2008; 
Zhou et al. 2005) for DNA typing to differentiate alleles from various chromosomes 
may also be explored. However, the multiplexing level achievable by each of these 
strategies would have to be considered. 
To be applied in clinical settings, the multiplex assay would have to be tested on 
larger cohorts of euploid and T21 cases. It would also be meaningful to study the 
effects of increasing the stringency of SPRT analysis, as well as the diagnostic 





























































































































































































































































































































































































































































































































































































































































































































Appendix II. Digital PCR data and interpretation by SPRT analysis 
Table i. 100% euploid or trisomy 21 placental DNA 
� , „ Plate • a Poisson-corrected Counts b Sample Case . Assay D Classification number � . . „ „ , Chr21 Ref chr 
Euploid Case 1 1 Assay 1 58 56 0.510 Unclass 
(N3747) Assay 2 72 68 0.517 Unclass 
Assay 3 48 63 0.432 Euploid 
Assay 4 69 55 0.557 Unclass 
Plate 1 Total 247 241 0.506 Euploid 
Case 2 1 Assay 1 48 37 0.566 Unclass 
(N3699) Assay 2 58 57 0.505 Euploid 
Assay 3 28 38 0.425 Euploid 
Assay 4 43 47 0.481 Euploid 
Plate 1 Total 178 178 0.499 Euploid 
Cases 1 Assay 1 39 33 0.538 Unclass 
(N3709) Assay 2 42 30 0.584 Unclass 
Assay 3 25 25 0.500 Unclass 
Assay 4 35 28 0.552 Unclass 
Plate 1 subtotal 141 116 0.547 Unclass 
2 Assay 1 29 30 0.491 Unclass 
Assay 2 38 24 0.614 Unclass 
Assay 3 22 21 0.513 Unclass 
Assay 4 58 43 0.573 Unclass 
Plate 1-2 subtotal 287 234 0.551 Unclass 
3 Assay 1 36 27 0.569 Unclass 
Assay 2 40 38 0.514 Unclass 
Assay 3 14 17 0.451 Unclass 
Assay 4 48 30 0.614 Unclass 
Plate 1-3 subtotal 425 346 0.551 Unclass 
4 Assay 1 31 26 0.547 Unclass 
Assay 2 37 21 0.641 T21 
Assay 3 23 43 0.343 Euploid 
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Assay 4 29 21 0.586 Unclass 
Plate 1-4 Total 545 457 0.544 Euploid 
Case 6 1 Assay 1 15 36 0.301 Euploid 
(N3700) Assay 2 42 33 0.558 Unclass 
Assay 3 30 28 0.519 Unclass 
Assay 4 17 27 0.392 Euploid 
Plate 1 Total 105 124 0.459 Euploid 
T21 Case 3 1 Assay 1 65 50 0.565 Unclass 
(N3634) Assay 2 101 56 0.644 T21 
Assay 3 66 56 0.543 Unclass 
Assay 4 85 49 0.634 T21 
Plate 1 Total 318 211 0.601 T21 
Case 4 1 Assay 1 72 54 0.575 Unclass 
(N3438) Assay 2 66 51 0.564 Unclass 
Assay 3 70 41 0.630 T21 
Assay 4 86 46 0.653 T21 
Plate 1 Total 295 192 0.606 T21 
a In this column, Assay 1 = PV2101，Assay 2 = PV2107a, Assay 3 = PV2102b，Assay 4 = PV2106_L~ 
b In this column, Unclass = Unclassified 
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Table ii. 50% euploid or trisomy 21 placental DNA/ maternal blood cell DNA 
mixture 
c • Plate . a Poisson-corrected Counts Sample Case number Assay p Classification 
num 议 Chr21 Refchr ' 
EuploidCase 1 1 Assay 1 45 Ts 0.563 Unclass 
(N3747) Assay 2 31 45 0.412 Unclass 
Assay 3 32 22 0.600 Unclass 
Assay 4 38 35 0.523 Unclass 
Plate 1 subtotal 146 135 0.519 Unclass 
2 Assay 1 28 23 0.553 Unclass 
Assay 2 23 22 0.512 Unclass 
Assay 3 23 15 0.597 Unclass 
Assay 4 29 26 0.529 Unclass 
Plate 1-2 subtotal 248 221 0.530 Unclass 
3 Assay 1 17 25 0.412 Unclass 
Assay 2 25 16 0.603 Unclass 
Assay 3 13 26 0.338 Unclass 
Assay 4 27 24 0.532 Unclass 
Plate 1-3 subtotal 331 311 0.515 Unclass 
4 Assay 1 15 9 0.627 Unclass 
Assay 2 14 15 0.482 Unclass 
Assay 3 18 17 0.515 Unclass 
Assay 4 21 18 0.527 Unclass 
Plate 1-4 subtotal 399 372 0.518 Unclass 
5 Assay 1 10 13 0.434 Unclass 
Assay 2 11 14 0.439 Unclass 
Assay 3 7 16 0.302 Unclass 
Assay 4 19 10 0.658 Unclass 
Plate 1-5 Total 447 426 0.512 Euploid 
Case 2 1 Assay 1 37 33 0.523 Unclass 
(N3699) Assay 2 31 42 0.425 Unclass 
Assay 3 29 37 0.442 Unclass 
Assay 4 39 26 0.601 Unclass 
Plate 1 subtotal 136 138 0.496 Unclass 
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2 Assay 1 32 25 0.566 Unclass 
Assay 2 27 24 0.532 Unclass 
Assay 3 10 17 0.368 Unclass 
Assay 4 24 18 0.563 Unclass 
Plate 1-2 Total 229 223 0.507 Euploid 
T21 Case 3 1 Assay 1 50 33 0.600 Unclass 
(N3634) Assay 2 56 47 0.545 Unclass 
Assay 3 46 28 0.620 Unclass 
Assay 4 56 36 0.611 Unclass 
Plate 1 Total 208 144 0.591 T21 
Case 4 1 Assay 1 92 56 0.623 T21 
(N3438) Assay 2 94 82 0.532 Unclass 
Assay 3 45 54 0.454 Unclass 
Assay 4 77 69 0.529 Unclass 
Plate 1 subtotal 308 261 0.541 Unclass 
2 Assay 1 55 52 0.511 Unclass 
Assay 2 63 47 0.574 Unclass 
Assay 3 47 56 0.455 Unclass 
Assay 4 69 43 0.614 T21 
Plate 1-2 Total 541 459 0.541 T21 
a In this column, Assay 1 = PV2101，Assay 2 = PV2107a, Assay 3 = PV2102b, Assay 4 = PV2106_L 
b In this column, Unclass = Unclassified 
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Table iii. 25% euploid or trisomy 21 placental DNA/ maternal blood cell DNA 
mixture 
» Poisson-corrected Counts .. b Sample Case Assa/ p^  Classification ^ number Chr21 Refchr 
Euploid Case 1 1 Assay 1 ^ ^ ^ ^nclass 
(N3747) Assay 2 66 69 0.487 Unclass 
Assay 3 55 48 0.534 Unclass 
Assay 4 68 62 0.523 Unclass 
Plate 1 subtotal 252 238 0.514 Unclass 
2 Assay 1 55 57 0.490 Unclass 
Assay 2 68 53 0.564 Unclass 
Assay 3 36 42 0.457 Unclass 
Assay 4 41 56 0.424 Unclass 
Plate 1-2 subtotal 452 446 0.503 Unclass 
3 Assay 1 45 57 0.438 Unclass 
Assay 2 63 42 0.599 Unclass 
Assay 3 38 32 0.539 Unclass 
Assay 4 49 30 0.620 Unclass 
Plate 1-3 subtotal 647 609 0.515 Unclass 
4 Assay 1 56 61 0.480 Unclass 
Assay 2 57 58 0.495 Unclass 
Assay 3 41 58 0.414 Unclass 
Assay 4 65 48 0.577 Unclass 
Plate 1-4 subtotal 867 834 0.510 Unclass 
5 Assay 1 35 49 0.413 Unclass 
Assay 2 55 39 0.585 Unclass 
Assay 3 32 38 0.461 Unclass 
Assay 4 45 51 0.464 Unclass 
Plate 1-5 Total 1033 1011 0.505 Euploid 
Case 2 1 Assay 1 49 59 0.457 Unclass 
(N3699) Assay 2 59 55 0.516 Unclass 
Assay 3 30 52 0.370 Unclass 
Assay 4 45 56 0.443 Unclass 
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Plate 1 Total 183 222 0.452 Euploid 
T21 Case 3 1 Assay 1 45 56 0.443 Unclass 
(N3634) Assay 2 66 47 0.583 Unclass 
Assay 3 39 45 0.466 Unclass 
Assay 4 52 49 0.511 Unclass 
Plate 1 subtotal 201 197 0.505 Unclass 
2 Assay 1 70 55 0.561 Unclass 
Assay 2 63 48 0.568 Unclass 
Assay 3 39 36 0.522 Unclass 
Assay 4 47 40 0.539 Unclass 
Plate 1-2 subtotal 419 375 0.528 Unclass 
3 Assay 1 51 42 0.548 Unclass 
Assay 2 66 37 0.644 Unclass 
Assay 3 35 35 0.500 Unclass 
Assay 4 47 48 0.494 Unclass 
Plate 1-3 Total 618 537 0.535 T21 
Case 4 1 Assay 1 46 36 0.562 Unclass 
(N3438) Assay 2 37 30 0.549 Unclass 
Assay 3 39 22 0.643 Unclass 
Assay 4 52 33 0.611 Unclass 
Plate 1 Total 174 121 0.590 T21 
a In this column, Assay 1 = PV2101, Assay 2 = PV2107a, Assay 3 = PV2102b, Assay 4 = PV2106_L 
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